WO2020014505A2 - COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS - Google Patents

COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS Download PDF

Info

Publication number
WO2020014505A2
WO2020014505A2 PCT/US2019/041438 US2019041438W WO2020014505A2 WO 2020014505 A2 WO2020014505 A2 WO 2020014505A2 US 2019041438 W US2019041438 W US 2019041438W WO 2020014505 A2 WO2020014505 A2 WO 2020014505A2
Authority
WO
WIPO (PCT)
Prior art keywords
domain
monomer
domain monomer
polypeptide
antigen binding
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2019/041438
Other languages
English (en)
French (fr)
Other versions
WO2020014505A3 (en
Inventor
Jonathan C. Lansing
Daniel ORTIZ
Carlos J. Bosques
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Momenta Pharmaceuticals Inc
Original Assignee
Momenta Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to CA3106242A priority Critical patent/CA3106242A1/en
Priority to MX2021000280A priority patent/MX2021000280A/es
Priority to KR1020217004250A priority patent/KR20210043582A/ko
Priority to BR112021000415-7A priority patent/BR112021000415A2/pt
Priority to AU2019301684A priority patent/AU2019301684A1/en
Priority to US17/259,443 priority patent/US20210317227A1/en
Priority to CN201980059592.5A priority patent/CN113382749A/zh
Priority to JP2021500881A priority patent/JP2021530992A/ja
Application filed by Momenta Pharmaceuticals Inc filed Critical Momenta Pharmaceuticals Inc
Priority to EP19833960.8A priority patent/EP3820518A4/en
Publication of WO2020014505A2 publication Critical patent/WO2020014505A2/en
Publication of WO2020014505A3 publication Critical patent/WO2020014505A3/en
Priority to IL280044A priority patent/IL280044A/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/72—Increased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Definitions

  • ADCC antibody-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • Protein engineering can enhance effector function-based cell killing
  • binding to FcyRIII can be modified through partial or complete afucosylation of one or more Fc domains. Such modification may alter the effector function.
  • some attempts to combine afucosylation with other methods to enhance binding to Fc gamma receptors failed to increase effector function despite increasing binding to FcyRIII, suggesting that improvement in FcyRIII binding beyond a threshold might not further improve effector function (Repp et al. (201 1) Combined Fc-protein- and Fc-glyco-engineering of scFv-Fc fusion proteins synergistically enhances CD16a binding but does not further enhance NK-cell mediated ADCC. J Immunol Methods. 373:67-78.).
  • the present disclosure features compositions and methods for combining the target-specificity of an antigen binding domain with at least two Fc domains to generate new therapeutics with unique biological activity.
  • the present disclosure contemplates combining an antigen binding domain of a single Fc-domain containing therapeutic, e.g., a known therapeutic antibody, with at least two Fc domains to generate a novel therapeutic with a biological activity greater than that of the single Fc- domain containing therapeutic.
  • a single Fc-domain containing therapeutic e.g., a known therapeutic antibody
  • the disclosure provides various methods for the assembly of constructs having at least two, e.g., multiple, Fc domains, and to control
  • compositions Such homogeneity in a pharmaceutical composition is desirable in order to ensure the safety, efficacy, uniformity, and reliability of the pharmaceutical composition.
  • compositions containing a construct or polypeptide complex or polypeptide described herein are afucosylated to at least some extent.
  • at least 5%, 10%, 15%, 20%, 25%, 30%, 35%, 40%, 45%, 50%, 60%, 70%, 80%, 90% or 95% of the glycans (e.g. , the Fc glycans) present in the composition lack a fucose residue.
  • 5%-60%, 5%-50%, 5%-40%, 10%-50%, 10%- 50%, 10%-40%, 20%-50%, or 20%-40% of the glycans lack a fucose residue.
  • compositions that are afucosylated to at least some extent can be produced by culturing cells producing the antibody in the presence of 1 ,3,4-Tri-0-acetyl-2-deoxy-2-fluoro-L-fucose inhibitor.
  • Relatively afucosylated forms of the constructs and polypeptides described herein can be produced using a variety of other methods, including: expressing in cells with reduced or no expression of FUT8 (e.g,, by knocking out FUT8 or reducing expression with RNAi (siRNA, miRNA or shRNA) and expressing in cells that overexpress beta- 1 ,4-mannosyl-glycoprotein 4-beta-N-acetylglucosaminyltransferase (GnT-lll).
  • the disclosure contemplates compositions comprising the Fc-antigen binding domain constructs described herein wherein at least 3% of the glycans present in the composition lack a fucose residue, i.e., at least 5% of the glycans in the composition are afucosylated.
  • the disclosure features an Fc-antigen binding domain construct including enhanced effector function, where the Fc-antigen binding domain construct includes an antigen binding domain and a first Fc domain joined to a second Fc domain by a linker, where the Fc-antigen binding domain construct has enhanced effector function in an antibody-dependent cytotoxicity (ADCC) assay, an antibody-dependent cellular phagocytosis (ADCP), and/or complement-dependent cytotoxicity (CDC) assay relative to a construct having a single Fc domain and the antigen binding domain.
  • ADCC antibody-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • CDC complement-dependent cytotoxicity
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including an antigen binding domain and a first Fc domain joined to a second Fc domain by a linker.
  • the disclosure features an Fc-antigen binding domain construct including an antigen binding domain and a first Fc domain joined to a second Fc domain by a linker, where the Fc- antigen binding domain construct includes a biological activity that is not exhibited by a construct having a single Fc domain and the antigen binding domain.
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain.
  • the antigen binding domain is joined to the first polypeptide and the second polypeptide or the third polypeptide, or to the second polypeptide and the third polypeptide, or the antigen binding domain is joined to the first polypeptide, the second polypeptide, and the third polypeptide.
  • the disclosure features an Fc-antigen binding domain construct including enhanced effector function
  • the Fc-antigen binding domain construct includes: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the Fc-antigen binding domain construct has enhanced effector function in an antibody-dependent cytotoxicity (ADCC) assay, an antibody-dependent cellular phago
  • ADCC antibody
  • the single Fc domain construct is an antibody.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the Fc-antigen binding domain construct includes a biological activity that is not exhibited by a construct having a single Fc domain and the antigen binding domain.
  • the biological activity is an Fc receptor mediated effector function, such as ADCC, ADCP and/or CDC activity (e.g., ADCC and ADCP activity, ADCC and CDC activity, ADCP and CDC activity, or ADCC, ADCP, and CDC activity).
  • ADCC Fc receptor mediated effector function
  • ADCP e.g., ADCC and ADCP activity, ADCC and CDC activity, ADCP and CDC activity, or ADCC, ADCP, and CDC activity.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including: i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a spacer joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain.
  • the antigen binding domain is joined to the first polypeptide and the second polypeptide or the third polypeptide, or to the second polypeptide and the third polypeptide, or the antigen binding domain is joined to the first polypeptide, the second polypeptide, and the third polypeptide.
  • the antigen binding domain is a Fab.
  • the antigen binding domain is part of the amino acid sequence of the first, second, or third polypeptide, and, in some embodiments, the antigen binding domain is a scFv.
  • the antigen binding domain includes a VH domain and a CH1 domain, and where the VH and CH1 domains are part of the amino acid sequence of the first, second, or third polypeptide.
  • the antigen binding domain further includes a VL domain, where, in some embodiments the Fc-antigen binding domain construct includes a fourth polypeptide including the VL domain.
  • the VH domain includes a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH domain including a sequence of an antibody set forth in Table 2
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence is at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH sequence of an antibody set forth in Table 2, or the VH domain includes a VH sequence of an antibody set forth in Table 2.
  • the antigen binding domain includes a set of CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences set forth in Table 1
  • the antigen binding domain includes CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences from a set of a VH and a VL sequence of an antibody set forth in Table 2
  • the antigen binding domain includes a VH domain including CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • a VL domain including CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence of an antibody set forth in Table 2, where the VH and the VL domain sequences, excluding the CDR-H1 , CDR-H2, CDR-H3, C
  • the Fc- antigen binding domain construct further includes an IgG CL antibody constant domain and an IgG CH1 antibody constant domain, where the IgG CH1 antibody constant domain is attached to the N-terminus of the first polypeptide or the second polypeptide by way of a linker.
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer.
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer.
  • the dimerization selectivity modules include an engineered cavity into the CH3 domain of one of the Fc domain monomers and an engineered protuberance into the CH3 domain of the other of the Fc domain monomers, where the engineered cavity and the engineered protuberance are positioned to form a protuberance-into-cavity pair of Fc domain monomers.
  • the engineered protuberance includes at least one modification selected from S354C, T366W, T366Y, T394W, T394F, and F405W
  • the engineered cavity includes at least one modification selected from Y349C, T366S, L368A, Y407V, Y407T, Y407A, F405A, and T394S.
  • one of the Fc domain monomers includes Y407V and Y349C and the other of the Fc domain monomers includes T366W and S354C.
  • the dimerization selectivity modules include a negatively-charged amino acid into the CH3 domain of one of the domain monomers and a positively-charged amino acid into the CH3 domain of the other of the Fc domain monomers, where the negatively-charged amino acid and the positively-charged amino acid are positioned to promote formation of an Fc domain.
  • each of the first Fc domain monomer and third Fc domain monomer includes D399K and either K409D or K409E
  • each of the first Fc domain monomer and third Fc domain monomer includes K392D and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370E
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439D
  • each of the first Fc domain monomer and third Fc domain monomer includes K392E and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370D
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439E
  • each of the second Fc domain monomer and fourth Fc domain monomer includes S354C and T366W and the third and fourth polypeptides each include Y349C, T366S, L368A, and
  • one or more linker in the Fc-antigen binding domain construct is a bond.
  • one or more linker in the Fc-antigen binding domain construct is a spacer.
  • the spacer includes a polypeptide having the sequence GGGGGGGGGGGGGGGGGG, GGGGS, GGSG,
  • GGSGGSGGS GGSGGSGGS, GGSGGSGGSGGS, GGSG, GGSG, GGSGGGSG,
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • the spacer is a glycine spacer, for example, one consisting of 4 to 30, 8 to 30, or 12 to 30 glycine residues, such as a spacer consisting of 20 glycine residues.
  • the antigen binding domain is joined to the Fc domain monomer by a linker.
  • the linker is a spacer.
  • At least one of the Fc domains includes at least one amino acid modification at position I253.
  • the each amino acid modification at position I253 is independently selected from I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L, I253M, I253N, I253P, I253Q, I253R, I253S, I253T, I253V, I253W, and I253Y.
  • each amino acid modification at position I253 is I253A.
  • At least one of the Fc domains includes at least one amino acid modification at position R292.
  • each amino acid modification at position R292 is independently selected from R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y.
  • each amino acid modification at position R292 is R292P.
  • one or more of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • each of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • the IgG is of a subtype selected from the group consisting of lgG1 , lgG2a, lgG2b, lgG3, and lgG4.
  • the N- terminal Asp in each of the fourth, fifth, sixth, and seventh polypeptides is mutated to Gin.
  • one or more of the fourth, fifth, sixth, and seventh polypeptides lack a C-terminal lysine. In some embodiments, each of the fourth, fifth, sixth, and seventh polypeptides lacks a C-terminal lysine.
  • the Fc- antigen binding domain construct further includes an albumin-binding peptide joined to the N-terminus or C-terminus of one or more of the polypeptides by a linker.
  • the disclosure features a cell culture medium including a population of Fc- antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, are structurally identical, and where the Fc-antigen binding domain constructs are present in the culture medium at a concentration of at least 0.1 mg/L, 10 mg/L, 25 mg/L, 50 mg/L, 75 mg/L, or 100 mg/L.
  • At least 75%%, at least 85%, or at least 95% of the Fc-antigen binding domain constructs, on a molar basis, are structurally identical.
  • the disclosure features a cell culture medium including a population of Fc- antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain.
  • At least 75%, at least 85%, or at least 95% of the Fc-antigen binding domain constructs, on a molar basis include the first Fc domain, the second Fc domain, and the antigen binding domain.
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; (2) a second polypeptide including a third Fc domain monomer; (3) a third polypeptide including a fourth Fc domain monomer; and (4) an antigen binding domain; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain; where the antigen binding domain is joined to the first polypeptide, second polypeptide, or third polypeptide, thereby forming an Fc-antigen binding domain construct; and where at least 50% of the Fc-antigen binding domain constructs in
  • the antigen binding domain is joined to the first polypeptide and the second polypeptide or the third polypeptide, or to the second polypeptide and the third polypeptide, or the antigen binding domain is joined to the first polypeptide, the second polypeptide, and the third polypeptide.
  • the antigen binding domain is a Fab.
  • the antigen binding domain is part of the amino acid sequence of the first, second, or third polypeptide, and, in some embodiments, the antigen binding domain is a scFv.
  • the antigen binding domain includes a VH domain and a CH1 domain, and where the VH and CH1 domains are part of the amino acid sequence of the first, second, or third polypeptide.
  • the antigen binding domain further includes a VL domain, where, in some embodiments the Fc-antigen binding domain construct includes a fourth polypeptide including the VL domain.
  • the VH domain includes a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH domain including a sequence of an antibody set forth in Table 2
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence is at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH sequence of an antibody set forth in T able 2
  • the VH domain includes a VH sequence of an antibody set forth in Table 2.
  • the antigen binding domain includes a set of CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences set forth in Table 1
  • the antigen binding domain includes CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences from a set of a VH and a VL sequences of an antibody set forth in Table 2
  • the antigen binding domain includes a VH domain including CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • a VL domain including CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence of an antibody set forth in Table 2, where the VH and the VL domain sequences, excluding the CDR-H1 , CDR-H2, CDR-H3, CDR-
  • the Fc-antigen binding domain construct further includes an IgG CL antibody constant domain and an IgG CH1 antibody constant domain, where the IgG CH1 antibody constant domain is attached to the N-terminus of the first polypeptide or the second polypeptide by way of a linker.
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer.
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer.
  • the dimerization selectivity modules include an engineered cavity into the CH3 domain of one of the Fc domain monomers and an engineered protuberance into the CH3 domain of the other of the Fc domain monomers, where the engineered cavity and the engineered protuberance are positioned to form a protuberance-into-cavity pair of Fc domain monomers.
  • the engineered protuberance includes at least one modification selected from S354C, T366W, T366Y, T394W, T394F, and F405W
  • the engineered cavity includes at least one modification selected from Y349C, T366S, L368A, Y407V, Y407T, Y407A, F405A, and T394S.
  • one of the Fc domain monomers includes Y407V and Y349C and the other of the Fc domain monomers includes T366W and S354C.
  • the dimerization selectivity modules include a negatively-charged amino acid into the CH3 domain of one of the domain monomers and a positively-charged amino acid into the CH3 domain of the other of the Fc domain monomers, where the negatively-charged amino acid and the positively-charged amino acid are positioned to promote formation of an Fc domain.
  • each of the first Fc domain monomer and third Fc domain monomer includes D399K and either K409D or K409E
  • each of the first Fc domain monomer and third Fc domain monomer includes K392D and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370E
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439D
  • each of the first Fc domain monomer and third Fc domain monomer includes K392E and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370D
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439E
  • each of the second Fc domain monomer and fourth Fc domain monomer includes S354C and T366W and the third and fourth polypeptides each include Y349C, T366S, L368A, and
  • the second polypeptide and the third polypeptide have the same amino acid sequence.
  • one or more linker in the Fc-antigen binding domain construct is a bond.
  • one or more linker in the Fc-antigen binding domain construct is a spacer.
  • the spacer includes a polypeptide having the sequence GGGGGGGGGGGGGGGGGG, GGGGS, GGSG, SGGG, GSGS, GSGSGS, GSGSGSGSGS, GSGSGSGSGSGS, GGSGGS, GGSGGSGGS,
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • the spacer is a glycine spacer, for example, one consisting of 4 to 30, 8 to 30, or 12 to 30 glycine residues, such as a spacer consisting of 20 glycine residues.
  • the antigen binding domain is joined to the Fc domain monomer by a linker.
  • the linker is a spacer.
  • At least one of the Fc domains includes at least one amino acid modification at position I253.
  • the each amino acid modification at position I253 is independently selected from I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L, I253M, I253N, I253P, I253Q, I253R, I253S, I253T, I253V, I253W, and I253Y.
  • each amino acid modification at position I253 is I253A.
  • At least one of the Fc domains includes at least one amino acid modification at position R292.
  • each amino acid modification at position R292 is independently selected from R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y.
  • each amino acid modification at position R292 is R292P.
  • one or more of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • each of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • the IgG is of a subtype selected from the group consisting of lgG1 , lgG2a, lgG2b, lgG3, and lgG4.
  • the N-terminal Asp in each of the first, second, third, and fourth polypeptides is mutated to Gin.
  • one or more of the first, second, third, and fourth polypeptides lack a C-terminal lysine. In some embodiments, each of the first, second, third, and fourth polypeptides lacks a C-terminal lysine.
  • the Fc-antigen binding domain construct further includes an albumin-binding peptide joined to the N-terminus or C-terminus of one or more of the polypeptides by a linker.
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; and e) a second antigen binding domain joined to the second polypeptide and/or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first and the second antigen binding domains bind different antigens.
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • the second polypeptide and the third polypeptide have different amino acid sequences
  • the first antigen binding domain is joined to the first polypeptide and the second antigen binding domain is joined to the second polypeptide and the third polypeptide.
  • each of the second Fc domain monomer and the fourth Fc domain monomer includes E357K and K370D
  • each of the first Fc domain monomer and the third Fc domain monomer includes K370D and E357K
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; e) a second antigen binding domain joined to the second polypeptide; and f) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first, the second, and the third antigen
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • the second polypeptide and the third polypeptide have different amino acid sequences
  • each of the second Fc domain monomer and the fourth Fc domain monomer includes D399K and K409D
  • each of the first Fc domain monomer and the third Fc domain monomer includes E357K and K370D.
  • the first or second antigen binding is a Fab. In some embodiments of the eleventh and twelfth aspects of the disclosure, the first and second antigen binding domain is a Fab. In some embodiments of the ninth aspect of the disclosure, the first, second, and third antigen binding domain is a Fab.
  • the first or second antigen binding is a scFv. In some embodiments of the eleventh and twelfth aspects of the disclosure, the first and second antigen binding domain is a scFv. In some embodiments of the ninth aspect of the disclosure, the first, second, and third antigen binding domain is a scFv.
  • the first or second antigen binding domain includes a VH domain and a CH1 domain, and where the VH and CH1 domains are part of the amino acid sequence of the first, second, or third polypeptide.
  • the antigen binding domain further includes a VL domain, where, in some embodiments the Fc-antigen binding domain construct includes a fourth polypeptide including the VL domain.
  • the VH domain includes a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH domain including a sequence of an antibody set forth in Table 2
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence is at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH sequence of an antibody set forth in T able 2
  • the VH domain includes a VH sequence of an antibody set forth in Table 2.
  • the first, second, or third antigen binding domain includes a VH domain and a CH1 domain, and where the VH and CH1 domains are part of the amino acid sequence of the first, second, or third polypeptide.
  • the antigen binding domain further includes a VL domain, where, in some embodiments the Fc-antigen binding domain construct includes a fourth polypeptide including the VL domain.
  • the VH domain includes a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH domain including a sequence of an antibody set forth in Table 2
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence is at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH sequence of an antibody set forth in Table 2, or the VH domain includes a VH sequence of an antibody set forth in Table 2.
  • the first or second antigen binding domain includes a set of CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences set forth in Table 1
  • the antigen binding domain includes CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences from a set of a VH and a VL sequence of an antibody set forth in Table 2
  • the antigen binding domain includes a VH domain including CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • a VL domain including CDR-L1 , CDR-L2, and CDR-L3 of a VL sequences of an antibody set forth in Table 2, where the VH and the VL domain sequences, excluding the CDR-H1 , CDR-H2, CDR-H3, CDR-
  • the first, second, or third antigen binding domain includes a set of CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences set forth in Table 1
  • the antigen binding domain includes CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences from a set of a VH and a VL sequence of an antibody set forth in Table 2
  • the antigen binding domain includes a VH domain including CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • a VL domain including CDR-L1 , CDR-L2, and CDR-L3 of a VL sequence of an antibody set forth in Table 2, where the VH and the VL domain sequences, excluding the CDR-H1 , CDR-H2, CDR-
  • the Fc-antigen binding domain construct further includes an IgG CL antibody constant domain and an IgG CH1 antibody constant domain, where the IgG CH1 antibody constant domain is attached to the N-terminus of the first polypeptide or the second polypeptide by way of a linker.
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer.
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer.
  • the dimerization selectivity modules include an engineered cavity into the CH3 domain of one of the Fc domain monomers and an engineered protuberance into the CH3 domain of the other of the Fc domain monomers, where the engineered cavity and the engineered protuberance are positioned to form a protuberance-into-cavity pair of Fc domain monomers.
  • the engineered protuberance includes at least one modification selected from S354C, T366W, T366Y, T394W, T394F, and F405W
  • the engineered cavity includes at least one modification selected from Y349C, T366S, L368A, Y407V, Y407T, Y407A, F405A, and T394S.
  • one of the Fc domain monomers includes Y407V and Y349C and the other of the Fc domain monomers includes T366W and S354C.
  • the dimerization selectivity modules include a negatively-charged amino acid into the CH3 domain of one of the domain monomers and a positively-charged amino acid into the CH3 domain of the other of the Fc domain monomers, where the negatively-charged amino acid and the positively-charged amino acid are positioned to promote formation of an Fc domain.
  • each of the first Fc domain monomer and third Fc domain monomer includes D399K and either K409D or K409E
  • each of the first Fc domain monomer and third Fc domain monomer includes K392D and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370E
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439D
  • each of the first Fc domain monomer and third Fc domain monomer includes K392E and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370D
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439E
  • each of the second Fc domain monomer and fourth Fc domain monomer includes S354C and T366W and the third and fourth polypeptides each include Y349C, T366S, L368A, and
  • one or more linker in the Fc-antigen binding domain construct is a bond.
  • one or more linker in the Fc-antigen binding domain construct is a spacer.
  • the spacer includes a polypeptide having the sequence GGGGGGGGGGGGGGGGGG, GGGGS, GGSG, SGGG, GSGS, GSGSGS, GSGSGSGSGS, GSGSGSGSGSGS, GGSGGS, GGSGGSGGS,
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • the spacer is a glycine spacer, for example, one consisting of 4 to 30, 8 to 30, or 12 to 30 glycine residues, such as a spacer consisting of 20 glycine residues.
  • one or more of the antigen binding domains is joined to the Fc domain monomer by a linker.
  • the linker is a spacer.
  • At least one of the Fc domains includes at least one amino acid modification at position I253.
  • the each amino acid modification at position I253 is independently selected from I253A, I253C, I253D, I253E,
  • each amino acid modification at position I253 is I253A.
  • At least one of the Fc domains includes at least one amino acid modification at position R292.
  • each amino acid modification at position R292 is independently selected from R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y.
  • each amino acid modification at position R292 is R292P.
  • one or more of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • each of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • the IgG is of a subtype selected from the group consisting of lgG1 , lgG2a, lgG2b, lgG3, and lgG4.
  • the N-terminal Asp in each of the first, second, third, and fourth polypeptides is mutated to Gin.
  • one or more of the first, second, third, and fourth polypeptides lack a C-terminal lysine.
  • each of the first, second, third, and fourth polypeptides lacks a C-terminal lysine.
  • the Fc-antigen binding domain construct further includes an albumin-binding peptide joined to the N-terminus or C- terminus of one or more of the polypeptides by a linker.
  • the disclosure features a composition including a substantially
  • an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including i) a third Fc domain monomer, ii) a fourth Fc domain monomer, and iv) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fifth Fc domain monomer combine
  • each of the first and third Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the first Fc domain monomer and the third Fc domain monomer
  • each of the second and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fifth Fc domain monomer
  • each of the fourth and sixth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the fourth Fc domain monomer and the sixth Fc domain monomer.
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including i) a third Fc domain monomer, ii) a fourth Fc domain monomer, and iv) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide;where the second Fc domain monomer and the fourth Fc domain monomer combine to form a first Fc domain and
  • each of the second and fourth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • each of the first and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the first Fc domain monomer and the fifth Fc domain monomer
  • each of the third and sixth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the third Fc domain monomer and the sixth Fc domain monomer.
  • the disclosure features a composition including a substantially homogenous population of an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and v) a second linker joining the second Fc domain monomer and the third Fc domain monomer; b) a second polypeptide including i) a fourth Fc domain monomer, ii) a fifth Fc domain monomer, iii) a sixth Fc domain monomer, iv) a third linker joining the fourth Fc domain monomer and the fifth Fc domain monomer; and v) a fourth linker joining the fifth Fc domain monomer and the sixth Fc domain monomer; c) a third polypeptide including a seventh Fc domain monomer;
  • each of the second and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fifth Fc domain monomer
  • each of the first and seventh Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the first Fc domain monomer and the seventh Fc domain monomer
  • each of the fourth and eighth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the fourth Fc domain monomer and the eighth Fc domain monomer
  • each of the third and ninth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the third Fc domain monomer and the ninth Fc domain monomer
  • each of the sixth and tenth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the sixth Fc domain monomer and the tenth Fc domain monomer.
  • the antigen binding domain is part of the amino acid sequence of one or more of the polypeptides, and, in some embodiments, the antigen binding domain is a scFv.
  • the antigen binding domain includes a VH domain and a CH1 domain, and where the VH and CH1 domains are part of the amino acid sequence of the first, second, or third polypeptide.
  • the antigen binding domain further includes a VL domain, where, in some embodiments the Fc-antigen binding domain construct includes a fourth polypeptide including the VL domain.
  • the VH domain includes a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH domain including a sequence of an antibody set forth in Table 2
  • the VH domain includes CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence is at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH sequence of an antibody set forth in Table 2, or the VH domain includes a VH sequence of an antibody set forth in Table 2.
  • the antigen binding domain includes a set of CDR-H1 , CDR-H2, CDR-H3, CDR-L1 , CDR-L2, and CDR-L3 sequences set forth in Table 1
  • the antigen binding domain includes CDR-H1 , CDR-H2, CDR-H3, CDR- L1 , CDR-L2, and CDR-L3 sequences from a set of a VH and a VL sequences of an antibody set forth in Table 2
  • the antigen binding domain includes a VH domain including CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2
  • a VL domain including CDR-L1 , CDR-L2, and CDR- L3 of a VL sequence of an antibody set forth in Table 2, where the VH and the VL domain sequences, excluding the CDR-H1 , CDR-H2, CDR-H
  • the Fc- antigen binding domain construct further includes an IgG CL antibody constant domain and an IgG CH1 antibody constant domain, where the IgG CH1 antibody constant domain is attached to the N-terminus of the first polypeptide or the second polypeptide by way of a linker.
  • the dimerization selectivity modules include an engineered cavity into the CH3 domain of one of the Fc domain monomers and an engineered protuberance into the CH3 domain of the other of the Fc domain monomers, where the engineered cavity and the engineered protuberance are positioned to form a protuberance-into-cavity pair of Fc domain monomers.
  • the engineered protuberance includes at least one modification selected from S354C, T366W, T366Y, T394W, T394F, and F405W
  • the engineered cavity includes at least one modification selected from Y349C, T366S, L368A, Y407V, Y407T, Y407A, F405A, and T394S.
  • one of the Fc domain monomers includes Y407V and Y349C and the other of the Fc domain monomers includes T366W and S354C.
  • the dimerization selectivity modules include a negatively-charged amino acid into the CH3 domain of one of the domain monomers and a positively-charged amino acid into the CH3 domain of the other of the Fc domain monomers, where the negatively-charged amino acid and the positively-charged amino acid are positioned to promote formation of an Fc domain.
  • each of the first Fc domain monomer and third Fc domain monomer includes D399K and either K409D or K409E
  • each of the first Fc domain monomer and third Fc domain monomer includes K392D and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370E
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439D
  • each of the first Fc domain monomer and third Fc domain monomer includes K392E and D399K
  • each of the first Fc domain monomer and third Fc domain monomer includes E357K and K370D
  • each of the first Fc domain monomer and third Fc domain monomer includes D356K and K439E
  • each of the second Fc domain monomer and fourth Fc domain monomer includes S354C and T366W and the third and fourth polypeptides each include Y349C, T366S, L368A, and
  • one or more linker in the Fc-antigen binding domain construct is a bond.
  • one or more linker in the Fc-antigen binding domain construct is a spacer.
  • the spacer includes a polypeptide having the sequence GGGGGGGGGGGGGGGGGG, GGGGS, GGSG, SGGG, GSGS, GSGSGS, GSGSGSGSGS, GSGSGSGSGSGS, GSGSGSGSGSGS, GGSGGS,
  • GGSGGSGGS GGSGGSGGS, GGSGGSGGSGGS, GGSG, GGSG, GGSGGGSG,
  • the spacer is a glycine spacer, for example, one consisting of 4 to 30, 8 to 30, or 12 to 30 glycine residues, such as a spacer consisting of 20 glycine residues.
  • the antigen binding domain is joined to the Fc domain monomer by a linker.
  • the linker is a spacer.
  • At least one of the Fc domains includes at least one amino acid modification at position I253.
  • the each amino acid modification at position I253 is independently selected from I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L, I253M, I253N, I253P, I253Q, I253R, I253S, I253T, I253V, I253W, and I253Y.
  • each amino acid modification at position I253 is I253A.
  • At least one of the Fc domains includes at least one amino acid modification at position R292.
  • each amino acid modification at position R292 is independently selected from R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y.
  • each amino acid modification at position R292 is R292P.
  • one or more of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • each of the Fc domain monomers includes an IgG hinge domain, an IgG CH2 antibody constant domain, and an IgG CH3 antibody constant domain.
  • the IgG is of a subtype selected from the group consisting of lgG1 , lgG2a, lgG2b, lgG3, and lgG4.
  • the N- terminal Asp in each of the polypeptides is mutated to Gin.
  • one or more of the polypeptides lack a C-terminal lysine. In some embodiments, each of the polypeptides lacks a C-terminal lysine.
  • the Fc- antigen binding domain construct further includes an albumin-binding peptide joined to the N-terminus or C-terminus of one or more of the polypeptides by a linker.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) a first antigen binding domain joined to the first polypeptide; and e) a second antigen binding domain joined to the second polypeptide and/or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, where the first and the second antigen binding domains bind different antigens, and where the Fc-antigen binding domain construct has enhanced effector function in an antibody-
  • the disclosure features an Fc-antigen binding domain construct including:
  • an Fc-antigen binding domain construct including:
  • the disclosure features a cell culture medium including a population of Fc- antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; and d) a first antigen binding domain joined to the first polypeptide; and e) a second antigen binding domain joined to the second polypeptide and/or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first Fc domain monomer
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; (2) a second polypeptide including a third Fc domain monomer; (3) a third polypeptide including a fourth Fc domain monomer; (4) a first antigen binding domain joined to the first polypeptide; and (5) a second antigen binding domain joined to the second polypeptide and/or third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain; where the antigen binding domain is joined to the first polypeptide, second polypeptide, or third polypeptide,
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • the second polypeptide and the third polypeptide have different amino acid sequences.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; e) a second antigen binding domain joined to the second polypeptide; and f) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first, the second, and the third antigen binding domains bind different antigens, and where the Fc-antigen binding domain construct
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; e) a second antigen binding domain joined to the second polypeptide; and f) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first, the second, and the third antigen binding domains bind different antigens, and where the Fc-antigen binding domain construct
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a spacer joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; e) a second antigen binding domain joined to the second polypeptide; and f) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain, and where the first, the second, and the third antigen binding domains bind different antigens.
  • the disclosure features a cell culture medium including a population of Fc-antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; b) a second polypeptide including a third Fc domain monomer; c) a third polypeptide including a fourth Fc domain monomer; d) a first antigen binding domain joined to the first polypeptide; e) a second antigen binding domain joined to the second polypeptide; and f) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a linker joining the first Fc domain monomer and the second Fc domain monomer; (2) a second polypeptide including a third Fc domain monomer; (3) a third polypeptide including a fourth Fc domain monomer; (4) a first antigen binding domain joined to the first polypeptide; (5) a second antigen binding domain joined to the second polypeptide; and (6) a third antigen binding domain joined to the third polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fourth Fc domain monomer combine to form a second Fc domain; where the antigen binding domain is joined to the first polypeptide, second
  • the first Fc domain monomer and the third Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the first Fc domain monomer and the third Fc domain monomer
  • the second Fc domain monomer and the fourth Fc domain monomer include complementary dimerization selectivity modules that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • the second polypeptide and the third polypeptide have different amino acid sequences.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and d) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide, where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fifth Fc domain
  • the disclosure features a Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fifth Fc
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first spacer joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second spacer joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first Fc domain and the second Fc domain monomer and the fifth Fc domain
  • the disclosure features a cell culture medium including a population of Fc-antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the first F
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and (2) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and (3) a third polypeptide including a fifth Fc domain monomer; (4) a fourth polypeptide including an sixth Fc domain monomer; and (5) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the first Fc domain monomer and the third Fc domain monomer combine to form a first F
  • each of the first and third Fc domain monomers includes a
  • each of the second and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fifth Fc domain monomer
  • each of the fourth and sixth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the fourth Fc domain monomer and the sixth Fc domain monomer.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the second Fc domain monomer and the fourth Fc domain monomer combine to form a first Fc domain and the first Fc domain monomer and the fifth Fc domain
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the second Fc domain monomer and the fourth Fc domain monomer combine to form a first Fc domain and the first Fc domain monomer and the fifth Fc domain
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first spacer joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second spacer joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide, where the second Fc domain monomer and the fourth Fc domain monomer combine to form a first Fc domain and the first Fc domain monomer and the fifth Fc domain
  • the disclosure features a cell culture medium including a population of Fc-antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and b) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and c) a third polypeptide including a fifth Fc domain monomer; d) a fourth polypeptide including an sixth Fc domain monomer; and e) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the second F
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, and iii) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and (2) a second polypeptide including iv) a third Fc domain monomer, v) a fourth Fc domain monomer, and vi) a second linker joining the third Fc domain monomer and the fourth Fc domain monomer; and (3) a third polypeptide including a fifth Fc domain monomer; (4) a fourth polypeptide including an sixth Fc domain monomer; and (5) an antigen binding domain joined to the first polypeptide, second polypeptide, third polypeptide, or fourth polypeptide; where the second Fc domain monomer and the fourth Fc domain monomer combine to form a first Fc domain
  • each of the second and fourth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fourth Fc domain monomer
  • each of the first and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the first Fc domain monomer and the fifth Fc domain monomer
  • each of the third and sixth Fc domain monomers includes a
  • complementary dimerization selectivity module that promote dimerization between the third Fc domain monomer and the sixth Fc domain monomer.
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and v) a second linker joining the second Fc domain monomer and the third Fc domain monomer; b) a second polypeptide including vi) a fourth Fc domain monomer, vii) a fifth Fc domain monomer, viii) a sixth Fc domain monomer, ix) a third linker joining the fourth Fc domain monomer and the fifth Fc domain monomer; and x) a fourth linker joining the fifth Fc domain monomer and the sixth Fc domain monomer; c) a third polypeptide including a seventh Fc domain monomer; d) a fourth polypeptide including an eighth Fc domain monomer
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first linker joining the first Fc domain monomer and the second Fc domain monomer; and v) a second linker joining the second Fc domain monomer and the third Fc domain monomer; b) a second polypeptide including vi) a fourth Fc domain monomer, vii) a fifth Fc domain monomer, viii) a sixth Fc domain monomer, ix) a third linker joining the fourth Fc domain monomer and the fifth Fc domain monomer; and x) a fourth linker joining the fifth Fc domain monomer and the sixth Fc domain monomer; c) a third polypeptide including a seventh Fc domain monomer; d) a fourth polypeptide including an eighth Fc domain monomer
  • the disclosure features an Fc-antigen binding domain construct including: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first spacer joining the first Fc domain monomer and the second Fc domain monomer; and v) a second spacer joining the second Fc domain monomer and the third Fc domain monomer; b) a second polypeptide including vi) a fourth Fc domain monomer, vii) a fifth Fc domain monomer, viii) a sixth Fc domain monomer, ix) a third spacer joining the fourth Fc domain monomer and the fifth Fc domain monomer; and x) a fourth spacer joining the fifth Fc domain monomer and the sixth Fc domain monomer; c) a third polypeptide including a seventh Fc domain monomer; d) a fourth polypeptide including an eighth Fc domain monomer
  • the disclosure features a cell culture medium including a population of Fc- antigen binding domain constructs, where at least 50% of the Fc-antigen binding domain constructs, on a molar basis, include: a) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first spacer joining the first Fc domain monomer and the second Fc domain monomer; and v) a second spacer joining the second Fc domain monomer and the third Fc domain monomer; b) a second polypeptide including vi) a fourth Fc domain monomer, vii) a fifth Fc domain monomer, viii) a sixth Fc domain monomer, ix) a third spacer joining the fourth Fc domain monomer and the fifth Fc domain monomer; and x) a fourth spacer joining the fifth Fc domain monomer and the sixth Fc domain monomer;
  • the disclosure features a method of manufacturing an Fc-antigen binding domain construct, the method including: a) culturing a host cell expressing: (1) a first polypeptide including i) a first Fc domain monomer, ii) a second Fc domain monomer, iii) a third Fc domain monomer, iv) a first spacer joining the first Fc domain monomer and the second Fc domain monomer; and v) a second spacer joining the second Fc domain monomer and the third Fc domain monomer; (2) a second polypeptide including vi) a fourth Fc domain monomer, vii) a fifth Fc domain monomer, viii) a sixth Fc domain monomer, ix) a third spacer joining the fourth Fc domain monomer and the fifth Fc domain monomer; and x) a fourth spacer joining the fifth Fc domain monomer and the sixth Fc domain monomer; (3) a third polypeptide including a seventh Fc domain monomer, ii) a second
  • each of the second and fifth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the second Fc domain monomer and the fifth Fc domain monomer
  • each of the first and seventh Fc domain monomers includes a
  • each of the fourth and eighth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the fourth Fc domain monomer and the eighth Fc domain monomer
  • each of the third and ninth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the third Fc domain monomer and the ninth Fc domain monomer
  • each of the sixth and tenth Fc domain monomers includes a complementary dimerization selectivity module that promote dimerization between the sixth Fc domain monomer and the tenth Fc domain monomer.
  • the Fc-antigen binding domain construct has reduced fucosylation.
  • less than 40%, 30%, 20%, 15%, 10% or 5% of the Fc domain monomers in a composition comprising an Fc-antigen binding domain construct are fucosylated.
  • the Fc domain monomer comprises the amino acid sequence of FIG. 53A (SEQ ID NO: 43) with up to 10 (9, 8, 7, 6, 5, 4, 3, 2 or 1) single amino acid changes in the CH3 domain.
  • the Fc domain monomer comprises the amino acid sequence of FIG. 53B (SEQ ID NO: 45) with up to 10 (9, 8, 7, 6, 5, 4, 3, 2 or 1) single amino acid changes in the CH3 domain.
  • the Fc domain monomer comprises the amino acid sequence of FIG. 53C (SEQ ID NO: 47) with up to 10 (9, 8, 7, 6, 5, 4, 3, 2 or 1) single amino acid changes in the CH3 domain.
  • the Fc domain monomer comprises the amino acid sequence of FIG. 53D (SEQ ID NO: 42) with up to 10 (9, 8, 7, 6, 5, 4, 3, 2 or 1) single amino acid changes in the CH3 domain.
  • the Fc domain monomer when the Fc domain monomer is at the carboxy-terminal end of a polypeptide, the Fc domain monomer does not include K447. In other embodiments, for example, when the Fc domain monomer is not at the carboxy-terminal end of a polypeptide, the Fc domain monomer includes K447.
  • the Fc domain monomer when the Fc domain monomer is amino terminal to a linker, the Fc domain monomer does not include the portion of the hinge from E216 to C220, inclusive, but does include the portion of the hinge from D221 to L235, inclusive. In other embodiments, for example, when the Fc domain monomer is carboxy-terminal to a CH1 domain, the Fc domain monomer includes the portion of the hinge from E216 to L235, inclusive. In some embodiments of all aspects of the disclosure, for example, when the Fc domain monomer is amino terminal to a linker, the Fc domain monomer does not include the portion of the hinge from E216 to C220, inclusive, but does include the portion of the hinge from D221 to L235, inclusive. In other embodiments, for example, when the Fc domain monomer is carboxy-terminal to a CH1 domain, the Fc domain monomer includes the portion of the hinge from E216 to L235, inclusive. In some embodiments of all aspects of the disclosure, for example, when the Fc domain mono
  • a hinge domain for example a hinge domain at the amino terminus of a polypeptide, has an Asp to Gin mutation at EU position 221 .
  • the Fc-antigen binding domain constructs of the disclosure are assembled from polypeptides, including polypeptides comprising two or more lgG1 Fc domain monomers, and such polypeptides are an aspect of the present disclosure.
  • the disclosure features a polypeptide comprising an antigen binding domain; a linker; a first IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; a second linker; a second IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; an optional third linker; and an optional third lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain, wherein at least one Fc domain monomer comprises mutations forming an engineered protuberance.
  • the antigen binding domain comprises an antibody heavy chain variable domain; the antigen binding domain comprises an antibody light chain variable domain; the first lgG1 Fc domain monomer comprises two or four reverse charge mutations and the second lgG1 Fc domain monomer comprises mutations forming an engineered protuberance; the first lgG1 Fc domain monomer comprises mutations forming an engineered protuberance and the second lgG1 Fc domain monomer comprises two or four reverse charge mutations; both the first lgG1 Fc domain monomer and the second IgG constant domain monomer comprise mutations forming an engineered protuberance; the polypeptide comprises a third linker and a third IgG 1 Fc domain monomer wherein the first IgG 1 Fc domain monomer, the second lgG1 Fc domain monomer and the third lgG1 Fc domain monomer each comprise mutations forming an engineered protuberance; the polypeptide comprises a third linker and a third lgG1
  • the lgG1 Fc domain monomers comprising mutations forming an engineered protuberance further comprise one, two or three reverse charge mutations; the mutations forming an engineered protuberance and the reverse charge mutations are in the CH3 domain; the mutations are within the sequence from EU position G341 to EU position K447, inclusive; the mutations are single amino acid changes; the second linker and the optional third linker comprise or consist of an amino acid sequence selected from the group consisting of:
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS, GGGSGGGSGGGS, SGGGSGGGSGGGSGGG, GGSGGGSGGGSGGGGS, GGGG, GGGGGGGGGGGGGG and GGGGGGGGGGGGGGGGGG;
  • the second linker and the optional third linker is a glycine spacer;
  • the second linker and the optional third linker independently consist of 4 to 30, 4 to 20, 8 to 30, 8 to 20, 12 to 20 or 12 to 30 glycine residues;
  • the second linker and the optional third linker consist of 20 glycine residues;
  • at least one of the Fc domain monomers comprises a single amino acid mutation at EU position I253 each amino acid mutation at EU position I253 is independently selected from the group consisting of I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K
  • each amino acid mutation at position I253 is I253A; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position R292; each amino acid mutation at EU position R292 is independently selected from the group consisting of R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y; each amino acid mutation at position R292 is R292P; each Fc domain monomer independently comprises or consists of an amino acid sequence selected from the group consisting of EPKSCDKTHTCPPCPAPELL and DKTHTCPPCPAPELL; the hinge portion of the second Fc domain monomer and the third Fc domain monomer have the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino
  • each Fc domain monomer independently comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10 single amino acid substitutions; up to 6 of the single amino acid substitutions are reverse charge mutations in the CH3 domain or are mutations forming an engineered protuberance; the single amino acid substitutions are within the sequence from EU position G341 to EU position K447, inclusive; at least one of the mutations forming an engineered protuberance is selected from the group consisting of T366Y, T366W, T394W, T394Y, F405W, S35
  • the antigen binding domain is a scFv; the antigen binding domain comprises a VH domain and a CH1 domain; the antigen binding domain further comprises a VL domain; the VH domain comprises a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1 ; the VH domain comprises CDR-H1 , CDR-H2, and CDR-H3 of a VH domain comprising a sequence of an antibody set forth in Table 2; the VH domain comprises CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2, and the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence, is at least 95% or 98% identical to the VH sequence of an antibody set forth in Table
  • polypeptide complex comprising two copies of the composition of described above joined by disulfide bonds between cysteine residues within the hinge of first or second lgG1 Fc domain monomers.
  • polypeptide complex comprising a polypeptide described above
  • polypeptide and the second polypeptide are joined by disulfide bonds between cysteine residues within the hinge domain of the first, second or third lgG1 Fc domain monomer of the polypeptide and the hinge domain of the second polypeptide.
  • the second polypeptide monomer comprises mutations forming an engineered cavity; the mutations forming the engineered cavity are selected from the group consisting of: Y407T, Y407A, F405A, T394S, T394W/Y407A, T366W/T394S,
  • the second polypeptide comprises the amino acid sequence of any of SEQ ID NOs: 42, 43, 45, and 47 having up to 10 single amino acid substitutions.
  • the disclosure features: a polypeptide comprising: an antigen binding domain; a linker; a first IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; a second linker; a second IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; an optional third linker; and an optional third lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain, wherein at least one Fc domain monomer comprises one, two or three reverse charge amino acid mutations.
  • the antigen binding domain comprises an antibody heavy chain variable domain; the antigen binding domain comprises an antibody light chain variable domain; the first lgG1 Fc domain monomer comprises a set of two reverse charge mutations selected from those in Table 5 or a set of four reverse charge mutation selected from those in Table 6 and the second IgG 1 Fc domain monomer comprises one, two or three reverse charge amino acid mutations selected from Table 4; the first lgG1 Fc domain monomer comprises one, two or three reverse charge amino acid mutations selected from Table 4 and the second lgG1 Fc domain monomer comprises a set of two reverse charge mutations selected from those in Table 5 or a set of four reverse charge mutation selected from those in Table 6; both the first lgG1 Fc domain monomer and the second IgG constant domain monomer comprise one, two or three reverse charge amino acid mutations selected from Table 4; the polypeptide further comprises a third linker and a third lgG1 Fc domain monomer wherein the first IgG 1 F
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • the second linker and the optional third linker is a glycine spacer; the second linker and the optional third linker independently consist of 4 to 30, 4 to 20, 8 to 30, 8 to 20, 12 to 20 or 12 to 30 glycine residues; the second linker and the optional third linker consist of 20 glycine residues; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position I253 each amino acid mutation at EU position I253 is independently selected from the group consisting of I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L,
  • each amino acid mutation at position I253 is I253A; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position R292; each amino acid mutation at EU position R292 is independently selected from the group consisting of R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y; each amino acid mutation at position R292 is R292P; each Fc domain monomer independently comprises or consists of an amino acid sequence selected from the group consisting of EPKSCDKTHTCPPCPAPELL and DKTHTCPPCPAPELL; the hinge portion of the second Fc domain monomer and the third Fc domain monomer have the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino
  • each Fc domain monomer independently comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10 single amino acid substitutions; up to 6 of the single amino acid substitutions are reverse charge mutations in the CH3 domain or are mutations forming an engineered protuberance; the single amino acid substitutions are within the sequence from EU position G341 to EU position K447, inclusive; at least one of the mutations forming an engineered protuberance is selected from the group consisting of T366Y, T366W, T394W, T394Y, F405W, S35
  • the antigen binding domain is a scFv; the antigen binding domain comprises a VH domain and a CH1 domain; the antigen binding domain further comprises a VL domain; the VH domain comprises a set of CDR-H1 , CDR-H2 and CDR-H3 sequences set forth in Table 1 ; the VH domain comprises CDR-H1 , CDR-H2, and CDR-H3 of a VH domain comprising a sequence of an antibody set forth in Table 2; the VH domain comprises CDR-H1 , CDR-H2, and CDR-H3 of a VH sequence of an antibody set forth in Table 2, and the VH sequence, excluding the CDR-H1 , CDR-H2, and CDR-H3 sequence, is at least 95% or 98% identical to the VH sequence of an antibody set forth in Table
  • polypeptide complex comprising two copies of any of the polypeptides described above joined by disulfide bonds between cysteine residues within the hinge of first or second lgG1 Fc domain monomers.
  • polypeptide complex comprising a polypeptide described above joined to a second polypeptide comprising and lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain, wherein the polypeptide and the second polypeptide are joined by disulfide bonds between cysteine residues within the hinge domain of the first, second or third lgG1 Fc domain monomer of the polypeptide and the hinge domain of the second polypeptide.
  • the second polypeptide monomer comprises one, two or three reverse charge mutations; the second polypeptide monomer comprises one, two or three reverse charge mutations selected from Table 4 and are complementary to the one, two or three reverse charge mutations selected Table 4 in the polypeptide; the second polypeptide comprises the amino acid sequence of any of SEQ ID NOs: 42, 43, 45, and 47 having up to 10 single amino acid substitutions.
  • the disclosure features a polypeptide comprising: a first lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; a second linker; a second lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; an optional third linker; and an optional third IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain, wherein at least one Fc domain monomer comprises mutations forming an engineered protuberance.
  • the polypeptide further comprises: an antibody heavy chain variable domain and CH1 domain amino terminal to the first lgG1 monomer or an scFv amino terminal to the first lgG1 monomer; the first lgG1 Fc domain monomer comprises two or four reverse charge mutations and the second lgG1 Fc domain monomer comprises mutations forming an engineered protuberance; the first IgG 1 Fc domain monomer comprises mutations forming an engineered protuberance and the second IgG 1 Fc domain monomer comprises two or four reverse charge mutations; both the first IgG 1 Fc domain monomer and the second IgG constant domain monomer comprise mutations forming an engineered protuberance; the polypeptide comprises a third linker and a third lgG1 Fc domain monomer wherein the first lgG1 Fc domain monomer, the second lgG1 Fc domain monomer and the third lgG1 Fc domain monomer each comprise mutations forming an engineered protuberance;
  • the lgG1 Fc domain monomers comprising mutations forming an engineered protuberance further comprise one, two or three reverse charge mutations; the mutations forming an engineered protuberance and the reverse charge mutations are in the CH3 domain; the mutations are within the sequence from EU position G341 to EU position K447, inclusive; the mutations are single amino acid changes; the second linker and the optional third linker comprise or consist of an amino acid sequence selected from the group consisting of:
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • the second linker and the optional third linker is a glycine spacer; the second linker and the optional third linker independently consist of 4 to 30, 4 to 20, 8 to 30, 8 to 20, 12 to 20 or 12 to 30 glycine residues; the second linker and the optional third linker consist of 20 glycine residues; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position I253 each amino acid mutation at EU position I253 is independently selected from the group consisting of I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L,
  • each amino acid mutation at position I253 is I253A; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position R292; each amino acid mutation at EU position R292 is independently selected from the group consisting of R292D, R292E, R292L, R292P, R292Q, R292R, R292T, and R292Y; each amino acid mutation at position R292 is R292P; each Fc domain monomer independently comprises or consists of an amino acid sequence selected from the group consisting of EPKSCDKTHTCPPCPAPELL and DKTHTCPPCPAPELL; the hinge portion of the second Fc domain monomer and the third Fc domain monomer have the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino
  • each Fc domain monomer independently comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • the CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • the single amino acid substitutions are selected from the group consisting of: T366Y, T366W, T394W, T394Y, F405W, S354C, Y349T, T394F, K409D, K409E, K392D, K392E, K370D, K370E, D399K, D399R, E357K, E357R, D356K, and D356R; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10 single amino acid substitutions; up to 6 of the single amino acid substitutions are reverse charge mutations in the CH3 domain or are mutation
  • substitutions are within the sequence from EU position G341 to EU position K447, inclusive; at least one of the mutations forming an engineered protuberance is selected from the group consisting of T366Y, T366W, T394W, T394Y, F405W, S354C, Y349T, and T394F; the two or four reverse charge mutations are selected from: K409D, K409E, K392D. K392E, K370D, K370E, D399K, D399R, E357K, E357R, D356K, and D356R.
  • the disclosure features a polypeptide comprising: a first lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; a second linker; a second lgG1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain; an optional third linker; and an optional third IgG 1 Fc domain monomer comprising a hinge domain, a CH2 domain and a CH3 domain, wherein at least one Fc domain monomer comprises one, two or three reverse charge amino acid mutations.
  • the polypeptide further comprises an antibody heavy chain variable domain and CH1 domain amino terminal to the first lgG1 Fc domain monomer or scFv amino terminal to the first lgG1 Fc domain monomer;
  • the first lgG1 Fc domain monomer comprises a set of two reverse charge mutations selected from those in Table 5 or a set of four reverse charge mutation selected from those in Table 6 and the second lgG1 Fc domain monomer comprises one, two or three reverse charge amino acid mutations selected from Table 4;
  • the first lgG1 Fc domain monomer comprises one, two or three reverse charge amino acid mutations selected from Table 4 and the second lgG1 Fc domain monomer comprises a set of two reverse charge mutations selected from those in Table 5 or a set of four reverse charge mutation selected from those in Table 6;
  • both the first lgG1 Fc domain monomer and the second IgG constant domain monomer comprise one, two or three reverse charge amino acid mutations selected from Table 4;
  • the polypeptide further comprises
  • the second linker and the optional third linker is a glycine spacer; the second linker and the optional third linker independently consist of 4 to 30, 4 to 20, 8 to 30, 8 to 20, 12 to 20 or 12 to 30 glycine residues; the second linker and the optional third linker consist of 20 glycine residues; at least one of the Fc domain monomers comprises a single amino acid mutation at EU position I253 each amino acid mutation at EU position I253 is independently selected from the group consisting of I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L, I253M, I253N, I253P, I253Q, I253R, I253S, I253T, I253V, I253W, and I253Y; each amino acid mutation at position I253 is I253A;
  • the hinge portion of the second Fc domain monomer and the third Fc domain monomer have the amino acid sequence DKTHTCPPCPAPELL; the hinge portion of the first Fc domain monomer has the amino acid sequence EPKSCDKTHTCPPCPAPEL; the hinge portion of the first Fc domain monomer has the amino acid sequence EPKSCDKTHTCPPCPAPEL and the hinge portion of the second Fc domain monomer and the third Fc domain monomer have the amino acid sequence
  • each Fc domain monomer independently comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • CH2 domains of each Fc domain monomer are identical and comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • each Fc domain monomer independently comprise the amino acid sequence:
  • the single amino acid substitutions are selected from the group consisting of: T366Y, T366W, T394W, T394Y, F405W, F405A, Y407A, S354C, Y349T, T394F, K409D, K409E, K392D, K392E, K370D, K370E, D399K, D399R, E357K, E357R, D356K, and D356R; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10 single amino acid substitutions; up to 6 of the single amino acid substitutions are reverse
  • nucleic acid molecule encoding any of the forgoing polypeptides of the forty first, forty second, forty third and forty fourth aspects.
  • an expression vector that includes a nucleic acid encoding any of the forgoing polypeptide; host cells containing the nucleic acids or expression vectors; host cells further containing a nucleic acid molecule encoding a polypeptide comprising an antibody VL domain (e.g., a nucleic acid molecule encoding a polypeptide comprising an antibody VL domain and an antibody CL domain); a host cell further containing a nucleic acid molecule encoding a polypeptide comprising an antibody VL domain and an antibody CL domain; a host cells further containing a nucleic acid molecule encoding a polypeptide comprising an lgG1 Fc domain monomer having no more than 10 single amino acid mutations; a host cell further containing a nucleic acid molecule encoding a polypeptide comprising lgG1 Fc domain monomer having no more than 10 single amino acid mutations.
  • the lgG1 Fc domain monomer comprises the amino acid sequence of
  • composition comprising any of the polypeptide or polypeptide complexes described herein.
  • less than 40%, 30%, 20%, 10%, 5%, 2% of the polypeptides have at least one fucose.
  • polypeptides of the of forty first, forty second, forty third and forty fourth aspects of the disclosure are useful as components of the various Fc-antigen binding domain constructs described herein.
  • the polypeptides of any of the first through fortieth aspects e.g., those can comprise an antigen binding domain
  • Fc domain monomer e.g., comprising or consisting of the amino acid sequence of any of SEQ ID Nos: 42, 43, 45 and 47 with no more than 8, 6, 5, 4, or 3 single amino acid substitutions
  • a cavity e.g., selected from: Y407
  • an Fc-antigen binding domain construct comprising:
  • first and third Fc domain monomers together form a first Fc domain
  • second and fifth Fc domain monomers together form a second Fc domain
  • fourth and sixth Fc monomers together form a third Fc domain
  • the first and second polypeptides are identical in sequence; the third and fourth polypeptides are identical in sequence; the fifth and sixth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, and the fifth and sixth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human IgG; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • the first and third Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions that promote homodi
  • substitutions that promote heterodimerization between the fourth and sixth Fc domain monomers are selected from substitutions in Table 4A and 4B; and the substitutions that promote heterodimerization are selected from substitutions in Table 3.
  • anFc-antigen binding domain construct comprising:
  • first and third Fc domain monomers together form a first Fc domain
  • second and fifth Fc domain monomers together form a second Fc domain
  • fourth and sixth Fc monomers together form a third Fc domain
  • an Fc-antigen binding domain construct comprising:
  • first and fifth Fc domain monomers together form a first Fc domain
  • third and sixth Fc domain monomers together form an second Fc domain
  • second and fourth Fc monomers together form a third Fc domain
  • the first and second polypeptides are identical in sequence; third and fourth polypeptides are identical in sequence; the fifth and sixth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, and the fifth and sixth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human lgG1 ; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • the second and fourth Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions that promote homo
  • an Fc-antigen binding domain construct comprising:
  • first and seventh Fc domain monomers together form a first Fc domain
  • fourth and eighth Fc domain monomers together form an second Fc domain
  • second and fifth Fc monomer together form a third Fc domain
  • third and ninth Fc domain monomers together form a fourth Fc domain
  • sixth and tenth Fc monomers together form a fifth Fc domain
  • the first heavy chain binding domain and first light chain binding domain together form a first Fab
  • the second heavy chain binding domain and second light chain binding domain together form a second Fab.
  • the first and second polypeptides are identical in sequence; the third and fourth polypeptides are identical in sequence; the fifth and sixth polypeptides are identical in sequence; the seventh and eighth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, the fifth and sixth polypeptides are identical in sequence, and the seventh and eighth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human lgG1 ;
  • the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • the third and ninth Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions that promote heterodimerization between the third and ninth Fc domain monomers
  • the sixth and tenth Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions that promote heterodimerization between the sixth and tenth Fc domain monomers; the substitutions that promote homodimerization are selected from substitutions in Table 4A and 4B; the substitutions that promote heterodimerization are selected from substitutions in Table 3.
  • an Fc-antigen binding domain construct comprising:
  • first and seventh Fc domain monomers together form a first Fc domain
  • fourth and eighth Fc domain monomers together form an second Fc domain
  • second and fifth Fc monomer together form a third Fc domain
  • third and ninth Fc domain monomers together form a fourth Fc domain
  • sixth and tenth Fc monomers together form a fifth Fc domain
  • the first heavy chain binding domain and first light chain binding domain together form a first Fab
  • the second heavy chain binding domain and second light chain binding domain together form a second Fab.
  • an Fc-antigen binding domain construct comprising:
  • first and fourth Fc domain monomers together form a first Fc domain
  • the second and seventh Fc domain monomers together form an second Fc domain
  • the fifth and eighth Fc monomers together form a third Fc domain
  • the third and ninth Fc domain monomers together form a fourth Fc domain
  • the sixth and tenth Fc monomers together form a fifth Fc domain
  • the first heavy chain binding domain and first light chain binding domain together form a first Fab
  • second heavy chain binding domain and second light chain binding domain together form a second Fab.
  • the first and second polypeptides are identical in sequence; the third and fourth polypeptides are identical in sequence; the fifth and sixth polypeptides are identical in sequence; the seventh and eighth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, the fifth and sixth polypeptides are identical in sequence, and the seventh and eighth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human lgG1 ; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • substitutions that promote heterodimerization between the sixth and tenth Fc domain monomers 4, 3, 2 or 1 single amino acid substitutions that promote heterodimerization between the sixth and tenth Fc domain monomers; the substitutions that promote homodimerization are selected from substitutions in Table 4A and 4B; and the substitutions that promote heterodimerization are selected from substitutions in Table 3.
  • an Fc-antigen binding domain construct comprising:
  • first and fourth Fc domain monomers together form a first Fc domain
  • the second and seventh Fc domain monomers together form an second Fc domain
  • the fifth and eighth Fc monomers together form a third Fc domain
  • the third and ninth Fc domain monomers together form a fourth Fc domain
  • the sixth and tenth Fc monomers together form a fifth Fc domain
  • the first heavy chain binding domain and first light chain binding domain together form a first Fab
  • second heavy chain binding domain and second light chain binding domain together form a second Fab.
  • an Fc-antigen binding domain construct comprising:
  • first and fifth Fc domain monomers together form a first Fc domain
  • third and sixth Fc domain monomers together form an second Fc domain
  • second and fourth Fc domain monomers together form a third Fc domain
  • the first heavy chain binding domain and first light chain binding domain together form a first Fab
  • the second heavy chain binding domain and second light chain binding domain together form a second Fab.
  • the first and second polypeptides are identical in sequence; the third and fourth polypeptides are identical in sequence; the fifth and sixth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, and the fifth and sixth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human lgG1 ; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • the second and fourth Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions that promote
  • an Fc-antigen binding domain construct comprising:
  • first and fifth Fc domain monomers together form a first Fc domain
  • third and sixth Fc domain monomers together form an second Fc domain
  • second and fourth Fc monomers together form a third Fc domain
  • the first light chain binding domain and third heavy chain binding domain together form a first Fab
  • the second light chain binding domain and fourth heavy chain binding domain together form a second Fab
  • the third light chain binding domain and first heavy chain binding domain together form a third Fab
  • fourth light chain binding domain and second heavy chain binding domain together form a second Fab
  • the first and second polypeptides are identical in sequence; the third and fourth polypeptides are identical in sequence; the fifth, sixth, seventh and eighth polypeptides are identical in sequence; the first and second polypeptides are identical in sequence, the third and fourth polypeptides are identical in sequence, and the fifth, sixth, seventh and eighth polypeptides are identical in sequence;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions;
  • the CH3 domain of each of the Fc domain monomers includes up to 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions compared to the amino acid sequence of human lgG1 ; each of the Fc domain monomers independently comprises the amino acid sequence of any of SEQ ID NOs:42, 43, 45, and 47 having up to 10, 8, 7, 6, 5, 4, 3, 2 or 1 single amino acid substitutions; the single amino acids substitutions are only in the CH3 domain;
  • the second and fourth Fc domain monomers comprise up to 8, 7, 6, 5, 4, 3, 2 or
  • each linker comprises or consists of an amino acid sequence selected from the group consisting of:GGGGGGGGGGGGGGGGGG, GGGGS, GGSG, SGGG, GSGS, GSGSGS, GSGSGSGSGS, GSGSGSGSGSGS, GGSGGS, GGSGGSGGS,
  • AAANSSIDLISVPVDSR GGSGGGSEGGGSEGGGSEGGGSEGGGSEGGGSGGGS,
  • each amino acid substitution at EU position I253 is independently selected from the group consisting of I253A, I253C, I253D, I253E, I253F, I253G, I253H, I253I, I253K, I253L, I253M, I253N, I253P, I253Q, I253R, I253S, I253T, I253V, I253W, and I253Y; at least one of the Fc domain monomers comprises a substitution at EU position R292; each amino acid substitution at EU position R292 is independently selected from the group consisting of R292D, R292E, R292L,
  • some or all of the Fc domain monomers can have one or both of a E345K and E430G amino acid substitution in addition to other amino acid substitutions or modifications.
  • the E345K and E430G amino acid substitutions can increase Fc domain multimerization (de Jong et al PLoS Biol 14(1): e1002344).
  • Fc domain monomer refers to a polypeptide chain that includes at least a hinge domain and second and third antibody constant domains (CH2 and CH3) or functional fragments thereof (e.g., at least a hinge domain or functional fragment thereof, a CH2 domain or functional fragment thereof, and a CH3 domain or functional fragment thereof) (e.g., fragments that that capable of (i) dimerizing with another Fc domain monomer to form an Fc domain, and (ii) binding to an Fc receptor).
  • a preferred Fc domain monomer comprises, from amino to carboxy terminus, at least a portion of lgG1 hinge, an lgG1 CH2 domain and an lgG1 CH3 domain.
  • an Fc domain monomer e.g., aa human lgG1 Fc domain monomer can extend from E316 to G446 or K447, from P317 to G446 or K447, from K318 to G446 or K447, from K318 to G446 or K447, from S319 to G446 or K447, from C320 to G446 or K447, from D321 to G446 or K447, from K322 to G446 or K447, from T323 to G446 or K447, from K323 to G446 or K447, from H324 to G446 or K447, from T325 to G446 or K447, or from C326 to G446 or K447.
  • the Fc domain monomer can be any immunoglobulin antibody isotype, including IgG, IgE, IgM, IgA, or IgD (e.g., IgG). Additionally, the Fc domain monomer can be an IgG subtype (e.g., lgG1 , lgG2a, lgG2b, lgG3, or lgG4) (e.g., human lgG1). The human lgG1 Fc domain monomer is used in the examples described herein.
  • the full hinge domain of human lgG1 extends from EU Numbering E316 to P230 or L235, the CH2 domain extends from A231 or G236 to K340 and the CH3 domain extends from G341 to K447. There are differing views of the position of the last amino acid of the hinge domain. It is either P230 or L235. In many examples herein the CH3 domain does not include K347. Thus, a CH3 domain can be from G341 to G446. In many examples herein a hinge domain can include E216 to L235. This is true, for example, when the hinge is carboxy terminal to a CH1 domain or a CD38 binding domain.
  • an Fc domain monomer does not include any portion of an immunoglobulin that is capable of acting as an antigen-recognition region, e.g., a variable domain or a complementarity determining region (CDR).
  • Fc domain monomers can contain as many as ten changes from a wild-type (e.g. , human) Fc domain monomer sequence (e.g., 1 -10, 1 -8, 1 -6, 1 -4 amino acid substitutions, additions, or deletions) that alter the interaction between an Fc domain and an Fc receptor.
  • Fc domain monomers can contain as many as ten changes (e.g., single amino acid changes) from a wild- type Fc domain monomer sequence (e.g., 1 -10, 1 -8, 1 -6, 1 -4 amino acid substitutions, additions, or deletions) that alter the interaction between Fc domain monomers.
  • a wild- type Fc domain monomer sequence e.g., 1 -10, 1 -8, 1 -6, 1 -4 amino acid substitutions, additions, or deletions
  • Fc domain refers to a dimer of two Fc domain monomers that is capable of binding an Fc receptor.
  • the two Fc domain monomers dimerize by the interaction between the two CH3 antibody constant domains, as well as one or more disulfide bonds that form between the hinge domains of the two dimerizing Fc domain monomers.
  • Fc-antigen binding domain construct refers to associated polypeptide chains forming at least two Fc domains as described herein and including at least one “antigen binding domain.”
  • Fc-antigen binding domain constructs described herein can include Fc domain monomers that have the same or different sequences.
  • an Fc-antigen binding domain construct can have three Fc domains, two of which includes lgG1 or lgG1 -derived Fc domain monomers, and a third which includes lgG2 or lgG2-derived Fc domain monomers.
  • an Fc- antigen binding domain construct can have three Fc domains, two of which include a“protuberance-into- cavity pair” and a third which does not include a“protuberance-into-cavity pair.”
  • An Fc domain forms the minimum structure that binds to an Fc receptor, e.g., FcyRI, FcyRIla, FcyRIIb, FcyRIIIa, FcyRIIIb, or FcyRIV.
  • the term“antigen binding domain” refers to a peptide, a polypeptide, or a set of associated polypeptides that is capable of specifically binding a target molecule.
  • the“antigen binding domain” is the minimal sequence of an antibody that binds with specificity to the antigen bound by the antibody.
  • SPR Surface plasmon resonance
  • various immunoassays known in the art e.g., Western Blots or ELISAs, can be used to assess antibody specificity for an antigen.
  • the“antigen binding domain” includes a variable domain or a complementarity determining region (CDR) of an antibody, e.g., one or more CDRs of an antibody set forth in Table 1 , one or more CDRs of an antibody set forth in Table 2, or the VH and/or VL domains of an antibody set forth in Table 2.
  • the antigen binding domain can include a VH domain and a CH1 domain, optionally with a VL domain.
  • the antigen binding domain is a Fab fragment of an antibody or a scFv.
  • An antigen binding domain may also be a synthetically engineered peptide that binds a target specifically such as a fibronectin-based binding protein (e.g., a fibronectin type III domain (FN3) monobody).
  • a fibronectin-based binding protein e.g., a fibronectin type III domain (FN3) monobody.
  • the term“antigen binding domain” refers to a peptide, a polypeptide, or a set of associated polypeptides that is capable of specifically binding a target molecule.
  • the“antigen binding domain” is the minimal sequence of an antibody that binds with specificity to the antigen bound by the antibody.
  • the“antigen binding domain” includes a variable domain or a complementarity determining region (CDR) of an antibody, e.g., one or more CDRs of an antibody set forth in Table 1 , one or more CDRs of an antibody set forth in Table 2, or the VH and/or VL domains of an antibody set forth in Table 2.
  • the CD38 binding domain can include a VH domain and a CH1 domain, optionally with a VL domain.
  • the antigen (e.g., CD38) binding domain is a Fab fragment of an antibody or a scFv.
  • a CD38 binding domain can include a“CD38 heavy chain binding domain” that comprises or consists of a VH domain and a CH1 domain and a” CD38 light chain binding domain” that comprises or consists of a VL domain and a CL domain.
  • a CD38 binding domain may also be a synthetically engineered peptide that binds a target specifically such as a fibronectin-based binding protein (e.g., a fibronectin type III domain (FN3) monobody).
  • CDRs Complementarity Determining Regions
  • Each variable domain typically has three CDR regions identified as CDR-L1 , CDR-L2 and CDR-L3, and CDR-H1 , CDR-H2, and CDR-H3).
  • Each complementarity determining region may include amino acid residues from a "complementarity determining region" as defined by Kabat (i.e.
  • a complementarity determining region can include amino acids from both a CDR region defined according to Kabat and a hypervariable loop.
  • FR Framework regions
  • Each variable domain typically has four FRs identified as FR1 , FR2, FR3 and FR4. If the CDRs are defined according to Kabat, the light chain FR residues are positioned at about residues 1 -23 (LCFR1), 35-49 (LCFR2), 57-88 (LCFR3), and 98-107 (LCFR4) and the heavy chain FR residues are positioned about at residues 1 -30 (HCFR1), 36-49 (HCFR2), 66-94 (HCFR3), and 103-1 13 (HCFR4) in the heavy chain residues.
  • the light chain FR residues are positioned about at residues 1 -25 (LCFR1), 33-49 (LCFR2), 53-90 (LCFR3), and 97-107 (LCFR4) in the light chain and the heavy chain FR residues are positioned about at residues 1 -25 (HCFR1), 33-52 (HCFR2), 56-95 (HCFR3), and 102-1 13 (HCFR4) in the heavy chain residues.
  • the FR residues will be adjusted accordingly.
  • Fv fragment is an antibody fragment which contains a complete antigen recognition and binding site.
  • This region consists of a dimer of one heavy and one light chain variable domain in tight association, which can be covalent in nature, for example, in a scFv. It is in this configuration that the three CDRs of each variable domain interact to define an antigen binding site on the surface of the VH-VL dimer.
  • the "Fab” fragment contains a variable and constant domain of the light chain and a variable domain and the first constant domain (CH1 ) of the heavy chain.
  • F(ab')2 antibody fragments include a pair of Fab fragments which are generally covalently linked near their carboxy termini by hinge cysteines.
  • Single-chain Fv or “scFv” antibody fragments include the VH and VL domains of antibody in a single polypeptide chain.
  • the scFv polypeptide further includes a polypeptide linker between the VH and VL domains, which enables the scFv to form the desired structure for antigen binding.
  • antibody constant domain refers to a polypeptide that corresponds to a constant region domain of an antibody (e.g., a CL antibody constant domain, a CH1 antibody constant domain, a CH2 antibody constant domain, or a CH3 antibody constant domain).
  • the term“promote” means to encourage and to favor, e.g., to favor the formation of an Fc domain from two Fc domain monomers which have higher binding affinity for each other than for other, distinct Fc domain monomers.
  • two Fc domain monomers that combine to form an Fc domain can have compatible amino acid modifications (e.g., engineered protuberances and engineered cavities, and/or electrostatic steering mutations) at the interface of their respective CH3 antibody constant domains.
  • the compatible amino acid modifications promote or favor the selective interaction of such Fc domain monomers with each other relative to with other Fc domain monomers which lack such amino acid modifications or with incompatible amino acid modifications. This occurs because, due to the amino acid modifications at the interface of the two interacting CH3 antibody constant domains, the Fc domain monomers to have a higher affinity toward each other than to other Fc domain monomers lacking amino acid modifications.
  • dimerization selectivity module refers to a sequence of the Fc domain monomer that facilitates the favored pairing between two Fc domain monomers.
  • “Complementary” dimerization selectivity modules are dimerization selectivity modules that promote or favor the selective interaction of two Fc domain monomers with each other. Complementary dimerization selectivity modules can have the same or different sequences. Exemplary complementary dimerization selectivity modules are described herein.
  • the term“engineered cavity” refers to the substitution of at least one of the original amino acid residues in the CH3 antibody constant domain with a different amino acid residue having a smaller side chain volume than the original amino acid residue, thus creating a three dimensional cavity in the CH3 antibody constant domain.
  • the term“original amino acid residue” refers to a naturally occurring amino acid residue encoded by the genetic code of a wild-type C H 3 antibody constant domain.
  • the term“engineered protuberance” refers to the substitution of at least one of the original amino acid residues in the C H 3 antibody constant domain with a different amino acid residue having a larger side chain volume than the original amino acid residue, thus creating a three dimensional protuberance in the C H 3 antibody constant domain.
  • the term“original amino acid residues” refers to naturally occurring amino acid residues encoded by the genetic code of a wild-type C H 3 antibody constant domain.
  • the term“protuberance-into-cavity pair” describes an Fc domain including two Fc domain monomers, wherein the first Fc domain monomer includes an engineered cavity in its C H 3 antibody constant domain, while the second Fc domain monomer includes an engineered protuberance in its C H 3 antibody constant domain.
  • the engineered protuberance in the C H 3 antibody constant domain of the first Fc domain monomer is positioned such that it interacts with the engineered cavity of the C H 3 antibody constant domain of the second Fc domain monomer without significantly perturbing the normal association of the dimer at the inter-C H 3 antibody constant domain interface.
  • heterodimer Fc domain refers to an Fc domain that is formed by the heterodimerization of two Fc domain monomers, wherein the two Fc domain monomers contain different reverse charge mutations (see, e.g., mutations in Table 4) that promote the favorable formation of these two Fc domain monomers.
  • an Fc construct having three Fc domains - one carboxyl terminal“stem” Fc domain and two amino terminal“branch” Fc domains - each of the amino terminal“branch” Fc domains may be a heterodimeric Fc domain (also called a“branch heterodimeric Fc domain”).
  • the term“structurally identical,” in reference to a population of Fc-antigen binding domain constructs, refers to constructs that are assemblies of the same polypeptide sequences in the same ratio and configuration and does not refer to any post-translational modification, such as glycosylation.
  • the term“homodimeric Fc domain” refers to an Fc domain that is formed by the homodimerization of two Fc domain monomers, wherein the two Fc domain monomers contain the same reverse charge mutations (see, e.g., mutations in Tables 5 and 6).
  • the carboxy terminal“stem” Fc domain may be a homodimeric Fc domain (also called a“stem homodimeric Fc domain”).
  • heterodimerizing selectivity module refers to engineered
  • Fc domain monomers containing heterodimerizing selectivity modules may combine to form a heterodimeric Fc domain. Examples of heterodimerizing selectivity modules are shown in Tables 3 and 4.
  • homodimerizing selectivity module refers to reverse charge mutations in an Fc domain monomer in at least two positions within the ring of charged residues at the interface between CH3 domains that promote homodimerization of the Fc domain monomer to form a homodimeric Fc domain. Examples of homodimerizing selectivity modules are shown in Tables 4 and 5.
  • the term“joined” is used to describe the combination or attachment of two or more elements, components, or protein domains, e.g., polypeptides, by means including chemical conjugation, recombinant means, and chemical bonds, e.g., peptide bonds, disulfide bonds and amide bonds.
  • two single polypeptides can be joined to form one contiguous protein structure through chemical conjugation, a chemical bond, a peptide linker, or any other means of covalent linkage.
  • an antigen binding domain is joined to a Fc domain monomer by being expressed from a contiguous nucleic acid sequence encoding both the antigen binding domain and the Fc domain monomer.
  • an antigen binding domain is joined to a Fc domain monomer by way of a peptide linker, wherein the N-terminus of the peptide linker is joined to the C-terminus of the antigen binding domain through a chemical bond, e.g., a peptide bond, and the C-terminus of the peptide linker is joined to the N-terminus of the Fc domain monomer through a chemical bond, e.g., a peptide bond.
  • the term“associated” is used to describe the interaction, e.g., hydrogen bonding, hydrophobic interaction, or ionic interaction, between polypeptides (or sequences within one single polypeptide) such that the polypeptides (or sequences within one single polypeptide) are positioned to form an Fc-antigen binding domain construct described herein (e.g., an Fc-antigen binding domain construct having three Fc domains).
  • an Fc-antigen binding domain construct described herein (e.g., an Fc-antigen binding domain construct having three Fc domains).
  • four polypeptides e.g., two polypeptides each including two Fc domain monomers and two polypeptides each including one Fc domain monomer, associate to form an Fc construct that has three Fc domains (e.g., as depicted in FIGS. 50 and 51).
  • the four polypeptides can associate through their respective Fc domain monomers.
  • the association between polypeptides does not include covalent interactions.
  • linker refers to a linkage between two elements, e.g., protein domains.
  • a linker can be a covalent bond or a spacer.
  • the term“bond” refers to a chemical bond, e.g., an amide bond or a disulfide bond, or any kind of bond created from a chemical reaction, e.g., chemical conjugation.
  • spacer refers to a moiety (e.g., a polyethylene glycol (PEG) polymer) or an amino acid sequence (e.g., a 3-200 amino acid, 3-150 amino acid, or 3-100 amino acid sequence) occurring between two polypeptides or polypeptide domains to provide space and/or flexibility between the two polypeptides or polypeptide domains.
  • An amino acid spacer is part of the primary sequence of a polypeptide (e.g., joined to the spaced polypeptides or polypeptide domains via the polypeptide backbone). The formation of disulfide bonds, e.g., between two hinge regions or two Fc domain monomers that form an Fc domain, is not considered a linker.
  • glycine spacer refers to a linker containing only glycines that joins two Fc domain monomers in tandem series.
  • a glycine spacer may contain at least 4, 8, or 12 glycines (e.g., 4-30, 8-30, or 12-30 glycines; e.g., 12-30, 4, 5, 6, 7, 8, 9, 10, 11 , 12, 13, 14, 15, 16, 17, 18, 19, 20, 21 , 22, 23, 24, 25, 26, 27, 28, 29, or 30 glycines).
  • a glycine spacer has the sequence of GGGGGGGGGGGGGGGGGGGGGG (SEQ ID NO: 27).
  • albumin-binding peptide refers to an amino acid sequence of 12 to 16 amino acids that has affinity for and functions to bind serum albumin.
  • An albumin-binding peptide can be of different origins, e.g., human, mouse, or rat.
  • an albumin-binding peptide is fused to the C-terminus of an Fc domain monomer to increase the serum half- life of the Fc-antigen binding domain construct.
  • An albumin-binding peptide can be fused, either directly or through a linker, to the N- or C-terminus of an Fc domain monomer.
  • purification peptide refers to a peptide of any length that can be used for purification, isolation, or identification of a polypeptide.
  • a purification peptide may be joined to a polypeptide to aid in purifying the polypeptide and/or isolating the polypeptide from, e.g., a cell lysate mixture.
  • the purification peptide binds to another moiety that has a specific affinity for the purification peptide.
  • such moieties which specifically bind to the purification peptide are attached to a solid support, such as a matrix, a resin, or agarose beads.
  • multimer refers to a molecule including at least two associated Fc constructs or Fc-antigen binding domain constructs described herein.
  • polynucleotide refers to an oligonucleotide, or nucleotide, and fragments or portions thereof, and to DNA or RNA of genomic or synthetic origin, which may be single- or double-stranded, and represent the sense or anti-sense strand. A single polynucleotide is translated into a single polypeptide.
  • polypeptide describes a single polymer in which the monomers are amino acid residues which are joined together through amide bonds.
  • a polypeptide is intended to encompass any amino acid sequence, either naturally occurring, recombinant, or synthetically produced.
  • amino acid positions refers to the position numbers of amino acids in a protein or protein domain.
  • the amino acid positions are numbered using the Kabat numbering system (Kabat et al., Sequences of Proteins of Immunological Interest, National Institutes of Health, Bethesda, Md., ed 5, 1991) where indicated (eg.g., for CDR and FR regions), otherwise the EU numbering is used.
  • FIGs. 24A-24D depict human lgG1 Fc domains numbered using the EU numbering system.
  • amino acid modification or refers to an alteration of an Fc domain polypeptide sequence that, compared with a reference sequence (e.g., a wild-type, unmutated, or unmodified Fc sequence) may have an effect on the pharmacokinetics (PK) and/or pharmacodynamics (PD) properties, serum half-life, effector functions (e.g., cell lysis (e.g., antibody-dependent cell-mediated toxicity(ADCC) and/or complement dependent cytotoxicity activity (CDC)), phagocytosis (e.g., antibody dependent cellular phagocytosis (ADCP) and/or complement-dependent cellular cytotoxicity (CDCC)), immune activation, and T-cell activation), affinity for Fc receptors (e.g., Fc-gamma receptors (FcyR) (e.g., FcyRI (CD64), FcyRIla (CD32), FcyRIIb (CD32), FcyRIII
  • amino acid modification includes amino acid substitutions, deletions, and/or insertions.
  • an amino acid modification is the modification of a single amino acid.
  • the amino acid modification is the modification of multiple (e.g., more than one) amino acids.
  • the amino acid modification may include a combination of amino acid substitutions, deletions, and/or insertions. Included in the description of amino acid modifications, are genetic (i.e., DNA and RNA) alterations such as point mutations (e.g., the exchange of a single nucleotide for another), insertions and deletions (e.g., the addition and/or removal of one or more nucleotides) of the nucleotide sequence that codes for an Fc polypeptide.
  • genetic i.e., DNA and RNA
  • point mutations e.g., the exchange of a single nucleotide for another
  • insertions and deletions e.g., the addition and/or removal of one or more nucleotides
  • At least one (e.g., one, two, or three) Fc domain within an Fc construct or Fc-antigen binding domain construct includes an amino acid modification.
  • the at least one Fc domain includes one or more (e.g., two, three, four, five, six, seven, eight, nine, ten, or twenty or more) amino acid modifications.
  • At least one (e.g., one, two, or three) Fc domain monomers within an Fc construct or Fc-antigen binding domain construct include an amino acid modification (e.g., substitution).
  • the at least one Fc domain monomers includes one or more (e.g., no more than two, three, four, five, six, seven, eight, nine, ten, or twenty) amino acid modifications (e.g., substitutions).
  • the term“percent (%) identity” refers to the percentage of amino acid (or nucleic acid) residues of a candidate sequence, e.g., the sequence of an Fc domain monomer in an Fc-antigen binding domain construct described herein, that are identical to the amino acid (or nucleic acid) residues of a reference sequence, e.g., the sequence of a wild-type Fc domain monomer, after aligning the sequences and introducing gaps, if necessary, to achieve the maximum percent identity (i.e., gaps can be introduced in one or both of the candidate and reference sequences for optimal alignment and non- homologous sequences can be disregarded for comparison purposes).
  • the percent amino acid (or nucleic acid) sequence identity of a given candidate sequence to, with, or against a given reference sequence is calculated as follows:
  • A is the number of amino acid (or nucleic acid) residues scored as identical in the alignment of the candidate sequence and the reference sequence
  • B is the total number of amino acid (or nucleic acid) residues in the reference sequence.
  • the percent amino acid (or nucleic acid) sequence identity of the candidate sequence to the reference sequence would not equal to the percent amino acid (or nucleic acid) sequence identity of the reference sequence to the candidate sequence.
  • a reference sequence aligned for comparison with a candidate sequence may show that the candidate sequence exhibits from 50% to 100% identity (e.g., 50% to 100%, 60% to 100%, 70% to 100%, 80% to 100%, 90% to 100%, 92% to 100%, 95% to 100%, 97% to 100%, 99% to 100%, or 99.5% to 100% identity), across the full length of the candidate sequence or a selected portion of contiguous amino acid (or nucleic acid) residues of the candidate sequence.
  • the length of the candidate sequence aligned for comparison purpose is at least 30%, e.g., at least 40%, e.g., at least 50%, 60%, 70%, 80%, 90%, or 100% of the length of the reference sequence.
  • an Fc domain monomer in an Fc construct described herein may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of a wild-type Fc domain monomer (e.g., SEQ ID NO: 42).
  • an Fc domain monomer in an Fc construct described herein may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of any one of SEQ ID NOs: 44, 46, 48, and 50-53.
  • an Fc domain monomer in the Fc construct may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of SEQ ID NO: 48, 52, and 53.
  • a spacer between two Fc domain monomers may have a sequence that is at least 75% identical (at least 75%, 77%, 79%, 81 %, 83%, 85%, 87%, 89%, 91 %, 93%, 95%, 97%, 99%, 99.5%, or 100% identical) to the sequence of any one of SEQ ID NOs: 1 -36 (e.g., SEQ ID NOs: 17, 18, 26, and 27) described further herein.
  • the term“host cell” refers to a vehicle that includes the necessary cellular components, e.g., organelles, needed to express proteins from their corresponding nucleic acids.
  • the nucleic acids are typically included in nucleic acid vectors that can be introduced into the host cell by conventional techniques known in the art (transformation, transfection, electroporation, calcium phosphate precipitation, direct microinjection, etc.).
  • a host cell may be a prokaryotic cell, e.g., a bacterial cell, or a eukaryotic cell, e.g., a mammalian cell (e.g., a CHO cell).
  • a host cell is used to express one or more polypeptides encoding desired domains which can then combine to form a desired Fc-antigen binding domain construct.
  • the term“pharmaceutical composition” refers to a medicinal or pharmaceutical formulation that contains an active ingredient as well as one or more excipients and diluents to enable the active ingredient to be suitable for the method of administration.
  • the pharmaceutical composition of the present disclosure includes pharmaceutically acceptable components that are compatible with the Fc- antigen binding domain construct.
  • the pharmaceutical composition is typically in aqueous form for intravenous or subcutaneous administration.
  • a“substantially homogenous population” of polypeptides or of an Fc construct is one in which at least 50% of the polypeptides or Fc constructs in a composition (e.g., a cell culture medium or a pharmaceutical composition) have the same number of Fc domains, as determined by nonreducing SDS gel electrophoresis or size exclusion chromatography.
  • a substantially homogenous population of polypeptides or of an Fc construct may be obtained prior to purification, or after Protein A or Protein G purification, or after any Fab or Fc-specific affinity chromatography only.
  • At least 55%, 60%, 65%, 70%, 75%, 80%, or 85% of the polypeptides or Fc constructs in the composition have the same number of Fc domains. In other embodiments, up to 85%, 90%, 92%, or 95% of the polypeptides or Fc constructs in the composition have the same number of Fc domains.
  • the term“pharmaceutically acceptable carrier” refers to an excipient or diluent in a pharmaceutical composition.
  • the pharmaceutically acceptable carrier must be compatible with the other ingredients of the formulation and not deleterious to the recipient.
  • the pharmaceutically acceptable carrier must provide adequate pharmaceutical stability to the Fc-antigen binding domain construct.
  • the nature of the carrier differs with the mode of administration. For example, for oral administration, a solid carrier is preferred; for intravenous administration, an aqueous solution carrier (e.g., WFI, and/or a buffered solution) is generally used.
  • “therapeutically effective amount” refers to an amount, e.g., pharmaceutical dose, effective in inducing a desired biological effect in a subject or patient or in treating a patient having a condition or disorder described herein. It is also to be understood herein that a“therapeutically effective amount” may be interpreted as an amount giving a desired therapeutic effect, either taken in one dose or in any dosage or route, taken alone or in combination with other therapeutic agents.
  • FIG. 1 is an illustration of an Fc-antigen binding domain construct (construct 1) containing two Fc domains and an antigen binding domain.
  • Each Fc domain is a dimer of two Fc domain monomers.
  • Two of the Fc domain monomers (106 and 108) contain a protuberance in its CH3 antibody constant domain, while the other two Fc domain monomers (1 12 and 1 14) contain a cavity in the juxtaposed position in its CH3 antibody constant domain.
  • the construct is formed from three Fc domain monomer containing polypeptides.
  • the first polypeptide (102) contains two protuberance-containing Fc domain monomers (106 and 108) linked by a spacer in a tandem series to an antigen binding domain containing a VH domain (1 10) on the N-terminus.
  • a VL containing domain (104) is joined to the VH domain.
  • Each of the second and third polypeptides (1 12 and 1 14) contains a cavity-containing Fc domain monomer.
  • FIG. 2 is an illustration of an Fc-antigen binding domain construct (construct 2) containing three Fc domains and an antigen binding domain.
  • the construct is formed from four Fc domain monomer containing polypeptides.
  • the first polypeptide (202) contains three protuberance-containing Fc domains (206, 208, and 210) linked by spacers in a tandem series to an antigen binding domain containing a VH domain (212) on the N-terminus.
  • a VL containing domain (204) is joined to the VH domain.
  • Each of the second, third, and fourth polypeptides (214, 216, and 218) contains a cavity-containing Fc domain monomer.
  • FIG. 3 is an illustration of an Fc-antigen binding domain construct (construct 3) containing two Fc domains and two antigen binding domains.
  • the construct is formed from three Fc domain monomer containing polypeptides.
  • the first polypeptide (302) contains two protuberance-containing Fc domain monomers (304 and 306) linked by a spacer in a tandem series.
  • Each of the second and third polypeptides (320 and 322) contains a cavity-containing Fc domain monomer (310 and 314) joined in tandem to an antigen binding domain containing a VH domain (316 and 318) on the N-terminus.
  • a VL containing domain (308 and 312) is joined to each VH domain.
  • FIG. 4 is an illustration of an Fc-antigen binding domain construct (construct 4) containing three Fc domains and three antigen binding domains.
  • the construct is formed from four Fc domain monomer containing polypeptides.
  • the first polypeptide (402) contains three protuberance-containing Fc domain monomers (404, 406, and 408) linked by spacers in a tandem series.
  • Each of the second, third, and fourth polypeptides (428, 430, and 432) contains a cavity-containing Fc domain monomer (426, 420, and 414) joined in tandem to an antigen binding domain containing a VH domain (422, 416, and 410) on the N- terminus.
  • a VL containing domain (424, 418, and 412) is joined to each VH domain.
  • FIG. 5 is an illustration of an Fc-antigen binding domain construct (construct 5) containing two Fc domains and three antigen binding domains.
  • the construct is formed from three Fc domain monomer containing polypeptides.
  • the first polypeptide (502) contains two protuberance-containing Fc domain monomers (508 and 506) linked by a spacer in a tandem series with an antigen binding domain containing a VH domain (510) at the N-terminus.
  • Each of the second and third polypeptides (524 and 526) contains a cavity-containing Fc domain monomer (516 and 522) joined in tandem to an antigen binding domain containing a VH domain (512 and 518) on the N-terminus.
  • FIG. 6 is an illustration of an Fc-antigen binding domain construct (construct 6) containing three Fc domains and four antigen binding domains.
  • the construct is formed from four Fc monomer containing polypeptides.
  • the first polypeptide (602) contains three protuberance-containing Fc domain monomers (606, 608, and 610) linked by spacers in a tandem series with an antigen binding domain containing a VH domain (612) at the N-terminus.
  • Each of the second, third, and fourth polypeptides (632, 634, and 636) contains a cavity-containing Fc domain monomer (618, 624, and 630) joined in tandem to an antigen binding domain containing a VH domain (616, 622, and 628) on the N-terminus.
  • a VL containing domain (604, 616, 622, and 628) is joined to each VH domain.
  • FIG. 7 is an illustration of an Fc-antigen binding domain construct (construct 7) containing three Fc domains and two antigen binding domains.
  • This Fc-antigen binding domain construct contains a dimer of two Fc domain monomers (706 and 718), wherein both Fc domain monomers contain different charged amino acids at their CH3-CH3 interface than the WT sequence to promote favorable electrostatic interactions between the two Fc domain monomers.
  • the construct is formed from four Fc domain monomer containing polypeptides.
  • Two polypeptides (702 and 724) each contain a protuberance- containing Fc domain monomer (710 and 720) linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (706 and 718) and an antigen binding domain containing a VH domain (712 and 714) on the N-terminus.
  • the third and fourth polypeptides (708 and 722) each contain a cavity-containing Fc domain monomer.
  • a VL containing domain (704 and 716) is joined to each VH domain.
  • FIG. 8 is an illustration of an Fc-antigen binding domain construct (construct 8) containing three Fc domains and two antigen binding domains.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (802 and 828) each contain a protuberance-containing Fc domain monomer (814 and 820) linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (810 and 816).
  • the third and fourth polypeptides (804 and 826) each contain a cavity-containing Fc domain monomer (808 and 824) joined in tandem to an antigen binding domain containing a VH domain (812 and 818) at the N-terminus.
  • a VL containing domain (806 and 822) is joined to each VH domain.
  • FIG. 9 is an illustration of an Fc-antigen binding domain construct (construct 9) containing three Fc domains and four antigen binding domains.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (902 and 936) each contain a protuberance-containing Fc domain monomer (918 and 928) linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (910 and 924) and an antigen binding domain containing a VH domain (908 and 920) at the N-terminus.
  • the third and fourth polypeptides (904 and 934) contain a cavity-containing Fc domain monomer (916 and 932) joined in a tandem series to an antigen binding domain containing a VH domain (912 and 926) at the N-terminus.
  • a VL containing domain (906, 914, 922, and 930) is joined to each VH domain.
  • FIG. 10 is an illustration of an Fc-antigen binding domain construct (construct 10) containing five Fc domains and two antigen binding domains. The construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1002 and 1032) each contain a protuberance-containing Fc domain monomer (1016 and 1030) linked by spacers in a tandem series to another protuberance- containing Fc domain monomer (1014 and 1028), an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1008 and 1022) and an antigen binding domain containing a VH domain (1006 and 1018) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (1012, 1010, 1026, and 1024) each contain a cavity-containing Fc domain monomer.
  • a VL containing domain (1004 and 1020) is joined to each VH domain.
  • FIG. 1 1 is an illustration of an Fc-antigen binding domain construct (construct 1 1) containing five Fc domains and four antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1 102 and 1 148) contain a protuberance-containing Fc domain monomer (1 1 18 and 1 132) linked by spacers in a tandem series to another protuberance- containing Fc domain monomer (1 120 and 1 130) and an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1 124 and 1 126).
  • the third, fourth, fifth, and sixth polypeptides (1 106, 1 104, 1 144, and 1 146) each contain a cavity-containing Fc domain monomer (1 1 16, 1 1 10, 1 134, and 1 140) joined in a tandem series to an antigen binding domain containing a VH domain (1 1 12, 1 122, 1 138, and 1 128) at the N-terminus.
  • a VL containing domain (1 108, 1 1 14, 1 135, and 1 142) is joined to each VH domain.
  • FIG. 12 is an illustration of an Fc-antigen binding domain construct (construct 12) containing five Fc domains and six antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1202 and 1256) contain a protuberance-containing Fc domain monomer (1224 and 1230) linked by spacers in a tandem series to another protuberance- containing Fc domain monomer (1226 and 1228), an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1210 and 1244), and an antigen binding domain containing a VH domain (1250 and 1248) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (1206, 1204, 1254, and 1252) each contain a cavity-containing Fc domain monomer (1222, 1216, 1232, and 1238) joined in a tandem series to an antigen binding domain containing a VH domain (1218, 1212, 1236, and 1242) at the N-terminus.
  • a V L containing domain (1208, 1214, 1220, 1234, 1240, and 1246) is joined to each VH domain.
  • FIG. 13 is an illustration of an Fc-antigen binding domain construct (construct 13) containing three Fc domains and two antigen binding domains.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (1302 and 1324) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1308 and 131 8) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (1312 and 1316) and an antigen binding domain containing a VH domain (1310 and 1314) at the N-terminus.
  • the third and fourth polypeptides (1306 and 1320) contain a cavity-containing Fc domain monomer.
  • a VL containing domain (1304 and 1322) is joined to each VH domain.
  • FIG. 14 is an illustration of an Fc-antigen binding domain construct (construct 14) containing three Fc domains and two antigen binding domains.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (1404 and 1426) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1308 and 131 8) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (1414 and 1418).
  • the third and fourth polypeptides each contain a cavity-containing Fc domain monomer (1410 and 1422) joined in a tandem series to an antigen binding domain containing a VH domain (1408 and 1416) at the N-terminus.
  • a VL containing domain (1406 and 1424) is joined to each VH domain.
  • FIG. 15 is an illustration of an Fc-antigen binding domain construct (construct 15) containing three Fc domains and four antigen binding domains.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (1502 and 1536) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1512 and 1524) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (1518 and 1522) and an antigen binding domain containing a VH domain (1514 and 1532) at the N-terminus.
  • the third and fourth polypeptides (1504 and 1534) contain a cavity-containing Fc domain monomer (1510 and 1526) joined in a tandem series to antigen binding domain containing a VH domain (1508 and 1530) at the N-terminus.
  • a VL containing domain (1506, 1516, 1520, and 1528) is joined to each VH domain.
  • FIG. 16 is an illustration of an Fc-antigen binding domain construct (construct 16) containing five Fc domains and two antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1602 and 1632) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1610 and 1624) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (1612 and 1622), a second protuberance-containing Fc domain monomer (1614 and 1620) and an antigen binding domain containing a VH domain (1616 and 1618) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (1608, 1606, 1626, and 1628) each contain a cavity-containing Fc domain.
  • a VL containing domain (1604 and 1630) is joined to each VH domain.
  • FIG. 17 is an illustration of an Fc-antigen binding domain construct (construct 17) containing five Fc domains and four antigen binding domains.
  • the construct is formed of six Fc monomer containing polypeptides.
  • Two polypeptides (1702 and 1748) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1718 and 1732) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (1720 and 1730) and a second protuberance-containing Fc domain monomer (1722 and 1728) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (1706, 1704, 1746, and 1744) contain a cavity-containing Fc domain monomer (1716, 1710, 1734, and 1740) joined in a tandem series to an antigen binding domain containing a VH domain (1712, 1724, 1738, and 1726) at the N-terminus.
  • a VL containing domain (1708, 1714, 1736, and 1742) is joined to each VH domain.
  • FIG. 18 is an illustration of an Fc-antigen binding domain construct (construct 18) containing five Fc domains and six antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1802 and 1856) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1818 and 1838) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (1820 and 1836), a second protuberance-containing Fc domain monomer (1822 and 1834) and an antigen binding domain containing a VH domain (1826 and 1830) at the N-terminus.
  • a VL containing domain (1808, 1814, 1824, 1832, 1842, and 1848) is joined to each VH domain.
  • FIG. 19 is an illustration of an Fc-antigen binding domain construct (construct 19) containing five Fc domains and two antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (1902 and 1932) contain a protuberance-containing Fc domain monomer (1912 and 1930) linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (1908 and 1926), a protuberance-containing Fc domain monomer (1916 and 1918), and an antigen binding domain containing a VH domain (1914 and 1920) at the N-terminus.
  • the third and fourth polypeptides (1910 and 1928) contain cavity-containing Fc domain monomers and the fifth and sixth polypeptides (1906 and 1924) contain cavity-containing Fc domain monomers.
  • a VL containing domain (1904 and 1922) is joined to each VH domain.
  • FIG. 20 is an illustration of an Fc-antigen binding domain construct (construct 20) containing five Fc domains and four antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (2002 and 2048) contain a protuberance-containing Fc domain monomer (2020 and 2022) linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2012 and 2030), and a protuberance-containing Fc domain monomer (2040 and 2038) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (2006, 2004, 2046, and 2044) each contain a cavity-containing Fc domain monomer (2018.
  • FIG. 21 is an illustration of an Fc-antigen binding domain construct (construct 21) containing five Fc domains and six antigen binding domains.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (2102 and 2156) contain a protuberance-containing Fc domain monomer (2120 and 2122) linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (21 12 and 2130), another protuberance-containing Fc domain monomer (2144 and 2142), and an antigen binding domain containing a VH domain (2148 and 2138) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (2106, 2104, 2154, and 2152) each contain a cavity-containing Fc domain monomer (21 18, 21 10, 2124, and 2132) joined in a tandem series to an antigen binding domain containing a VH domain (21 14, 2150, 2128, and 2136) at the N-terminus.
  • a V L containing domain (2108, 21 16, 2126, 2134, 2140, and 2146) is joined to each VH domain.
  • FIG. 22 is an illustration of an Fc-antigen binding domain construct (construct 22) containing two Fc domains and three antigen binding domains with two different specificities.
  • the construct is formed of three Fc domain monomer containing polypeptides.
  • the first polypeptide (2202) contains a
  • a VL containing domain (2204, 2212, and 2218) is joined to each VH domain.
  • FIG. 23 is an illustration of an Fc-antigen binding domain construct (construct 23) containing three Fc domains and four antigen binding domains with two different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (2302) contains three protuberance-containing Fc domain monomers (2310, 2308, and 2306) linked by spacers in a tandem series with an antigen binding domain of a first specificity containing a VH domain (2330) at the N- terminus.
  • the second, third, and fourth polypeptides (2336, 2334, and 2332) contain a cavity-containing Fc domain monomer (2312, 2318, and 2324) joined in a tandem series with an antigen binding domain of a second specificity containing a VH domain (2316, 2322, and 2328) at the N-terminus.
  • a VL containing domain (2304, 2314, 2320, and 2326) is joined to each VH domain.
  • FIG. 24 is an illustration of an Fc-antigen binding domain construct (construct 24) containing three Fc domains and four antigen binding domains with two different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (2402 and 2436) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2410 and 2412) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (2426 and 2424) and an antigen binding domain of a first specificity containing a VH domain (2430 and 2420) at the N-terminus.
  • the third and fourth polypeptides (2404 and 2434) contain a cavity- containing Fc domain monomer (2408 and 2414) joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (2432 and 2418).
  • a VL containing domain (2406, 2416, 2422, and 2428) is joined to each VH domain.
  • FIG. 25 is an illustration of an Fc-antigen binding domain construct (construct 25) containing three Fc domains and four antigen binding domains with two different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • Two polypeptides (2502 and 2536) contain a protuberance-containing Fc domain monomer (2516 and 2518) linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2508 and 2526) and an antigen binding domain of a first specificity containing a VH domain (2532 and 2530) at the N-terminus.
  • the second and third polypeptides contain a cavity- containing Fc domain monomer (2514 and 2520) joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (2510 and 2524) at the N-terminus.
  • a VL containing domain 2506, 2512, 2522, and 2528 is joined to each VH domain.
  • FIG. 26 is an illustration of an Fc-antigen binding domain construct (construct 26) containing five Fc domains and six antigen binding domains with two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (2602 and 2656) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2618 and 2620) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (2642 and 2640), a second protuberance-containing Fc domain monomer (2644 and 2638), and an antigen binding domain of a first specificity containing a VH domain (2648 and 2634) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (2606, 2604, 2654, and 2652) contain a cavity-containing Fc domain monomer (2616, 2610, 2622, and 2628) joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (2612, 2650, 2626, and 2632) at the N-terminus.
  • a VL containing domain (2608, 2614, 2624, 2630, 2636, and 2646) is joined to each VH domain.
  • FIG. 27 is an illustration of an Fc-antigen binding domain construct (construct 27) containing five Fc domains and six antigen binding domains with two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (2702 and 2756) contain a
  • protuberance-containing Fc domain monomer (2720 and 2722) linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2712 and 2730), a protuberance-containing Fc domain monomer (2744 and 2742) and an antigen binding domain of a first specificity containing a VH domain (2748 and 2738) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (2706, 2704, 2754, and 2752) contain a cavity-containing Fc domain monomer ( 2718, 2724, 2710, and 2732) joined in tandem to an antigen binding domain of a second specificity containing a VH domain (2714, 2728, 2750, and 2736) at the N-terminus.
  • a VL containing domain (2708, 2716, 2726, 2743, 2740, and 2746) is joined to each VH domain.
  • FIG. 28 is an illustration of an Fc-antigen binding domain construct (construct 28) containing five Fc domains and six antigen binding domains with two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (2802 and 2856) contain a
  • protuberance-containing Fc domain monomer (2824 and 2830) linked by spacers in a tandem series to a second protuberance-containing Fc domain monomer (2826 and 2828), an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (2810 and 2844), and an antigen binding domain of a first specificity containing a VH domain (2850 and 2848) at the N-terminus.
  • the third, fourth, fifth, and sixth polypeptides (2806, 2804, 2854, and 2852) contain a cavity- containing Fc domain monomer (2822, 2816, 2832, and 2838) joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (2818, 2812, 2836, and 2842) at the N- terminus.
  • a VL containing domain (2808, 2814, 2820, 2834, 2840, and 2846) is joined to each VH domain.
  • FIG. 29 is an illustration of an Fc-antigen binding domain construct (construct 29) containing two Fc domains and two antigen binding domains with two different specificities.
  • the construct is formed of three Fc domain monomer containing polypeptides.
  • the first polypeptide (2902) contains two protuberance-containing Fc domain monomers (2908 and 2906), each with a different set of
  • heterodimerization mutations linked by a spacer in a tandem series to an antigen binding domain of a first specificity containing a VH domain (2918).
  • the second polypeptide (2920) contains a cavity- containing Fc domain monomer (2910) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (2914) at the N- terminus.
  • the third polypeptide (2916) contains a cavity-containing Fc domain monomer with a second set of heterodimerization mutations.
  • a VL containing domain (2904 and 2912) is joined to each VH domain.
  • FIG. 30 is an illustration of an Fc-antigen binding domain construct (construct 30) containing two Fc domains and three antigen binding domains with two different specificities.
  • the construct is formed of three Fc domain monomer containing polypeptides.
  • the first polypeptide (3002) contains two protuberance-containing Fc domain monomers (3008 and 3006), each with a different set of
  • the second polypeptide (3024) contains a cavity-containing Fc domain monomer (3010) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3014) at the N-terminus.
  • the third polypeptide (3026) contains a cavity-containing Fc domain monomer (3016) with a first second of heterodimerization mutations joined in a tandem series to an antigen binding domain of a first specificity containing a VH domain (3020) at the N-terminus.
  • a VL containing domain (3004, 3012, and 3018) is joined to each VH domain.
  • FIG. 31 is an illustration of an Fc-antigen binding domain construct (construct 31) containing two Fc domains and three antigen binding domains with three different specificities.
  • the construct is formed of three Fc domain monomer containing polypeptides.
  • the first polypeptide (3102) contains two protuberance-containing Fc domain monomers (3108 and 3106), each with a different set of
  • the second polypeptide (3126) contains a cavity-containing Fc domain monomer (31 10) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (31 14) at the N-terminus.
  • the third polypeptide (3124) contains a cavity-containing Fc domain monomer (31 16) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (3120) at the N-terminus.
  • a VL containing domain (3104, 31 12, and 31 18) is joined to each VH domain.
  • FIG. 32 is an illustration of an Fc-antigen binding domain construct (construct 32) containing three Fc domains and three antigen binding domains with two different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (3202) contains three protuberance-containing Fc domain monomers (3210, 3208, and 3206), the third with a different set of heterodimerization mutations than the first two, linked by spacers in a tandem series to an antigen binding domain of a first specificity containing a VH domain (3226) at the N-terminus.
  • the second and third polypeptides (3230 and 3228) contain a cavity-containing Fc domain monomer (3212 and 3218) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3216 and 3222) at the N-terminus.
  • the fourth polypeptide (3224) contains a cavity-containing Fc domain monomer with a second set of heterodimerization mutations.
  • a VL containing domain (3204, 3214, and 3220) is joined to each VH domain.
  • FIG. 33 is an illustration of an Fc-antigen binding domain construct (construct 33) containing three Fc domains and four antigen binding domains with two different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (3302) contains three protuberance-containing Fc domain monomers (3310, 3308, and 3306), the third with a different set of heterodimerization mutations than the first two, linked by spacers in a tandem series to an antigen binding domain of a first specificity containing a VH domain (3330) at the N-terminus.
  • the second and third polypeptides (3336 and 3334) contain a cavity-containing Fc domain monomer (3312 and 3318) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3316 and 3322) at the N-terminus.
  • the fourth polypeptide (3322) contains a cavity-containing Fc domain monomer (3324) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a first specificity containing a VH domain (3328) at the N-terminus.
  • a VL containing domain (3304, 3314, 3320, and 3326) is joined to each VH domain.
  • FIG. 34 is an illustration of an Fc-antigen binding domain construct (construct 34) containing three Fc domains and four antigen binding domains with three different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (3402) contains three protuberance-containing Fc domain monomers (3410, 3408, and 3406), the third with a different set of heterodimerization mutations than the first two, linked by spacers in a tandem series to an antigen binding domain of a first specificity containing a VH domain (3430) at the N-terminus.
  • the second and third polypeptides (3436 and 3434) contain a cavity-containing Fc domain monomer (3412 and 3418) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3416 and 3422) at the N-terminus.
  • the fourth polypeptide (3432) contains a cavity-containing Fc domain monomer (3424) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (3428) at the N-terminus.
  • a VL containing domain (3404, 3414, 3420, and 3426) is joined to each VH domain.
  • FIG. 35 is an illustration of an Fc-antigen binding domain construct (construct 35) containing three Fc domains and four antigen binding domains with three different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (3502) contains an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3510) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (3526) with a first set of heterodimerization mutations and an antigen binding domain of a first specificity containing a VH domain (3530) at the N-terminus.
  • the second polypeptide (3536) contains an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3512) linked by a spacer in a tandem series to a protuberance-containing Fc domain monomer (3524) with a second set of heterodimerization mutations and an antigen binding domain of a first specificity containing a VH domain (3520) at the N-terminus.
  • the third polypeptide (3504) contains a cavity- containing Fc domain monomer (3508) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3532) at the N- terminus.
  • the fourth polypeptide (3534) contains a cavity-containing Fc domain monomer (3514) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (3518) at the N-terminus.
  • a VL containing domain (3506, 3516, 3522, and 3528) is joined to each VH domain.
  • FIG. 36 is an illustration of an Fc-antigen binding domain construct (construct 36) containing five Fc domains and four antigen binding domains with two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (3602 and 3644) contain a protuberance-containing Fc domain monomer (3614 and 3616), with a first set of heterodimerization mutations, linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3610 and 3620), another protuberance- containing Fc domain monomer (3634 and 3632), with a second set of heterodimerization mutations, and an antigen binding domain of a first specificity containing a VH domain (3638 and 3628) at the N-terminus.
  • the third and fourth polypeptides (3612 and 3618) contain a cavity-containing Fc domain monomer with a first set of heterodimerization mutations.
  • the fifth and six polypeptides (3604 and 3642) contain a cavity- containing Fc domain monomer (3608 and 3622) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3640 and 3626) at the N-terminus.
  • a VL containing domain (3606, 3624, 3630, and 3636) is joined to each VH domain.
  • FIG. 37 is an illustration of an Fc-antigen binding domain construct (construct 37) containing five Fc domains and six antigen binding domains with three different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (3702 and 3756) contain a cavity- containing Fc domain monomer (3720 and 3722), with a first set of heterodimerization mutations, linked by spacers in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3712 and 3730), another protuberance-containing Fc domain monomer (3744 and 3742), with a second set of heterodimerization mutations, and an antigen binding domain of a first specificity containing a VH domain (3748 and 3738) at the N-terminus.
  • the third and fourth polypeptides (3706 and 3754) contain a cavity-containing Fc domain monomer (3718 and 3724) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3714 and 3728) at the N-terminus.
  • the fifth and sixth polypeptides (3704 and 3752) contain a cavity-containing Fc domain monomer (3710 and 3732) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (3750 and 3736) at the N-terminus.
  • a VL containing domain (3708, 3716, 3726, 3234, 3740, and 3746) is joined to each VH domain.
  • FIG. 38 is an illustration of an Fc-antigen binding domain construct (construct 38) containing three Fc domains and four antigen binding domains with three different specificities.
  • the construct is formed of four Fc domain monomer containing polypeptides.
  • the first polypeptide (3802) contains a protuberance- containing Fc domain monomer (3816), with a first set of heterodimerization mutations, linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3808) and an antigen binding domain of a first specificity containing a VH domain (3832) at the N-terminus.
  • the second polypeptide (3836) contains a protuberance-containing Fc domain monomer (3818), with a second set of heterodimerization mutations, linked by a spacer in a tandem series to an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3826) and an antigen binding domain of a first specificity containing a VH domain (3830) at the N-terminus.
  • the third polypeptide (3804) contains a cavity-containing Fc domain monomer (3814) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3810) at the N-terminus.
  • the fourth polypeptide (3834) contains a cavity-containing Fc domain monomer (3820) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (3824) at the N-terminus.
  • a VL containing domain (3806, 3812, 3822, and 3828) is joined to each VH domain.
  • FIG. 39 is an illustration of an Fc-antigen binding domain construct (construct 39) containing five Fc domains and four antigen binding domains of two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (3902 and 3944) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (3912 and 3914) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (3932 and 3930), with a first set of heterodimerization mutations, a second protuberance-containing Fc domain monomer (3934 and 3928) with a second set of heterodimerization mutations, and an antigen binding domain of a first specificity containing a VH domain (3938 and 3924) at the N-terminus.
  • the third and fourth polypeptides (3910 and 3916) contain a cavity-containing Fc domain monomer with a first set of heterodimerization mutations.
  • the fifth and sixth polypeptides (3904 and 3942) contain a cavity- containing Fc domain monomer (3908 and 3918) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (3940 and 3922) at the N-terminus.
  • a VL containing domain (3906, 3920, 3926, and 3936) is joined to each VH domain.
  • FIG. 40 is an illustration of an Fc-antigen binding domain construct (construct 40) containing five Fc domains and six antigen binding domains of three different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (4002 and 4056) contain an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (4018 and 4020) linked by spacers in a tandem series to a protuberance-containing Fc domain monomer (4042 and 4040), with a first set of heterodimerization mutations, a second protuberance-containing Fc domain monomer (4044 and 4038), with a second set of heterodimerization mutations, and an antigen binding domain of a first specificity containing a VH domain (4048 and 4034) at the N-terminus.
  • the third and fourth polypeptides (4006 and 4054) contain a cavity-containing Fc domain monomer (4016 and 4022) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (4012 and 4026) at the N-terminus.
  • the fifth and sixth polypeptides (4004 and 4052) contain a cavity-containing Fc domain monomer (4010 and 4028) with a second set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (4050 and 4032) at the N-terminus.
  • a VL containing domain (4008, 4014, 4024, 4030, 4036, and 4046) is joined to each VH domain.
  • FIG. 41 is an illustration of an Fc-antigen binding domain construct (construct 41) containing five Fc domains and four antigen binding domains of two different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (4102 and 4144) contain a
  • protuberance-containing Fc domain monomer (41 18 and 4124), with a first set of heterodimerization mutations, linked by spacers in a tandem series to second protuberance-containing Fc domain monomer (4120 and 4122), with a second set of heterodimerization mutations, an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (4108 and 4134), and an antigen binding domain of a first specificity containing a VH domain (4140 and 4138) at the N-terminus.
  • the third and fourth polypeptides (4104 and 4142) contain a cavity-containing Fc domain monomer (41 16 and 4126) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (41 12 and 4130) at the N-terminus.
  • the fifth and sixth polypeptides (41 10 and 4132) contain a cavity-containing Fc domain monomer with a second set of heterodimerization mutations.
  • a VL containing domain (4106, 41 14, 4128, and 4136) is joined to each VH domain.
  • FIG. 42 is an illustration of an Fc-antigen binding domain construct (construct 42) containing five Fc domains and six antigen binding domains of three different specificities.
  • the construct is formed of six Fc domain monomer containing polypeptides.
  • Two polypeptides (4202 and 4256) contain a protuberance-containing Fc domain monomer (4224 and 4230), with a first set of heterodimerization mutations, linked by spacers in a tandem series to a second protuberance-containing Fc domain monomer (4226 and 4228), with a second set of heterodimerization mutations, an Fc domain monomer containing different charged amino acids at the CH3-CH3 interface than the WT sequence (4210 and 4244), and an antigen binding domain of a first specificity containing a VH domain (4250 and 4248) at the N-terminus.
  • the third and fourth polypeptides (4206 and 4254) contain a cavity-containing Fc domain monomer (4222 and 4232) with a first set of heterodimerization mutations joined in a tandem series to an antigen binding domain of a second specificity containing a VH domain (4218 and 4236) at the N- terminus.
  • the fifth and sixth polypeptides (4204 and 4252) contain a cavity-containing Fc domain monomer (4216 and 4238) with a second set of heterodimerzation mutations joined in a tandem series to an antigen binding domain of a third specificity containing a VH domain (4212 and 4242) at the N- terminus.
  • a VL containing domain (4208, 4214, 4220, 4234, 4240, and 4246) is joined to each VH domain.
  • FIG. 43 is a picture of a non-reducing SDS-PAGE gel showing the expression and purity of Rituximab (Rtxn), an anti-CD20 lgG1 mAB, and constructs 7, 13, 19, and 1 .
  • FIG. 44 is a gel showing expression of various Fc-antigen binding domain constructs.
  • the first three lanes show expression of an Fc-antigen binding domain construct at various ratios of the three separate polypeptides.
  • the fourth lane shows expression of a SIF3 construct (a construct with three Fc domains which does not contain an antigen binding domain) and the fifth lane shows expression of a construct with five Fc domains which does not contain an antigen binding domain.
  • the sixth lane is a molecular weight marker.
  • FIG. 45 is two graphs showing the results of surface plasmon resonance (SPR) assays.
  • the results show that the Fc3Y (a construct having the structure of Construct 13 (FIG.13)) binds much stronger to its CTLA-4 target than the corresponding parent monoclonal antibody (mAb) while the Fc3l (a construct having the structure of Construct 7 (FIG. 7)) has similar binding affinity as the parent mAb.
  • the results show that afucosylating the antibody increases cell-surface FcyRIIIa binding ⁇ 10-fold, while using various Fc-antigen binding domain constructs enhances binding ⁇ 300-800 fold.
  • FIG. 46 shows two graphs showing the results of two cell-surface FcyR binding binding assays.
  • the graph on the left shows binding affinities by various constructs to FcyRIIIa.
  • Afucosylation of a mAb with the same CDRs as Gazyva, a commercially available anti-CD20 antibody enhances binding ⁇ 10-fold, while all Fc-antigen binding domain constructs show enhanced binding >100-fold over the parent mAb.
  • the graph on the right shows binding affinities by various constructs to FcyRIIa. Afucosylation of athe mAb had no effect on binding, while all Fc-antigen binding domain constructs show enhanced binding >100-fold over the parent mAb.
  • the first graph shows that the S3Y Fc-antigen binding domain construct can mediate CDC.
  • the middle graph shows that both the SAI and S3Y Fc-antigen binding domain constructs exhibit >100-fold enhanced potency in an ADCP FcyRIla reporter assay.
  • the third graph shows that the SAI and S3Y Fc-antigen binding domain constructs exhibit enhanced ADCC activity relative to the fucosylated mAb and similar activity to the afucosylated mAb.
  • FIG. 48 is three graphs showing the results of CDC, ADCP, and ADCC assays with various anti- CTLA-4 constructs targeting CTLA-4 tranfected HEK cells.
  • the first graph shows that the SAI (an Fc- antigen binding domain construct having the structure shown in FIG.7) and S3Y (an Fc-antigen binding domain construct having the structure shown in FIG.13) constructs mediate enhanced CDC.
  • the second graph shows that the SAI and S3Y constructs mediate enhanced ADCP
  • the third graph shows that both the SAI and S3Y Fc-antigen binding domain constructs exhibit enhanced ADCC activity relative to the fucosylated mAb and similar activity to the afucosylated mAb.
  • FIG. 49 is three graphs showing the results of ADCC, ADCP, and CDC assays with various anti- PD-L1 constructs targeting PD-L1 transfected HEK cells.
  • the first graph shows that both the SAI (a construct having the structure of Fc-antigen binding domain construct 7 (FIG.7)) and S3Y Fc-antigen binding domain (a construct having the structure of Fc-antigen binding domain construct 13 (FIG.13)) constructs exhibit similar ADCC activity relative to the fucosylated and afucosylated mAbs.
  • the second graph shows that the SAI and S3Y constructs mediate enhanced ADCP
  • the third graph shows that the S3Y construct can mediate CDC.
  • FIG. 50 shows the size distribution by non-reducing SDS-PAGE of Fc construct A and Fc construct B in unpurified media.
  • FIG. 51 shows the expression and assembly of Fc construct A and another Fc construct having three Fc domains but without electrostatic steering mutations in the“stem” subunits.
  • FIG. 52 is a schematic representation of three exemplary ways the antigen binding domain can be joined to the Fc domain of an Fc construct.
  • Panel A shows a heavy chain component of an antigen binding domain can be expressed as a fusion protein of an Fc chain and a light chain component can be expressed as a separate polypeptide.
  • Panel B shows an scFv expressed as a fusion protein of the long Fc chain.
  • Panel C shows heavy chain and light chain components expressed separately and exogenously added and joined to the Fc-antigen binding domain construct with a chemical bond.
  • FIG. 53A depicts the amino acid sequence of a human lgG1 (SEQ ID NO: 43) with EU numbering.
  • the hinge region is indicated by a double underline, the CH2 domain is not underlined and the CH3 region is underlined.
  • FIG. 53B depicts the amino acid sequence of a human lgG1 (SEQ ID NO: 45) with EU numbering.
  • the hinge region which lacks E216-C220, inclusive, is indicated by a double underline, the CH2 domain is not underlined and the CH3 region is underlined and lacks K447.
  • FIG. 53C depicts the amino acid sequence of a human lgG1 (SEQ ID NO: 47) with EU numbering.
  • the hinge region is indicated by a double underline, the CH2 domain is not underlined and the CH3 region is underlined and lacks 447K.
  • FIG. 53D depicts the amino acid sequence of a human lgG1 (SEQ ID NO: 42) with EU numbering.
  • the hinge region which lacks E216-C220, inclusive, is indicated by a double underline, the CH2 domain is not underlined and the CH3 region is underlined.
  • FIG. 54 is a graph showing the induction of complement dependent cytotoxicity (CDC) in Daudi cells by anti-CD20 construct 7, anti-CD20 construct 13, Gazyva, and fucosylated anti-CD20 lgG1 antibody (obinutuzumab).
  • CDC complement dependent cytotoxicity
  • FIG. 55 is a graph showing the induction of FcyRIla signaling (fold induction) by anti-CD20 construct 7, anti-CD20 construct 13, and fucosylated and afucosylated anti-CD20 lgG1 antibody (obinutuzumab) in an ADCP reporter assay.
  • FIG. 56 is a graph showing the induction of FcyRIIIa signaling (fold induction) by anti-CD20 construct 7, anti-CD20 construct 13, and fucosylated and afucosylated anti-CD20 lgG1 antibody (obinutuzumab) in an ADCC reporter assay.
  • FIG. 57 is a graph showing the depletion of CD19+ B cells in human whole blood by fucosylated and afucosylated anti-CD20 construct 13 and fucosylated and afucosylated obinutuzumab monoclonal antibody.
  • FIG. 58 is a graph showing the reduction in tumor growth in a mouse lymphoma model after injection with a single dose of anti-CD20 construct 13, the fucosylated obinutuzumab monoclonal antibody, or the daratumumab monoclonal antibody, or after injection with multiple doses of anti-CD20 construct 13.
  • FIG. 59 is a graph showing the results of an ADCC reporter assay comparing anti-CD20 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • FIG. 60 is a graph depicting the results of an ADCP reporter assay comparing anti-CD20 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • FIG. 61 is a graph depicting the results of an analysis of the depletion of CD19+ B cells from whole blood induced by treatment with anti-CD20 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • FIG. 62 is a graph depicting the results of an analysis of ADCC of human lung cancer cells treated with anti-PD-L1 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • FIG. 63 is a graph depicting the results of an analysis ADCP of human lung cancer cells treated with anti-PD-L1 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • FIG. 64 is a graph depicting the results of an analysis CDC of PD-L1 -transfected HEK cells treated with anti-PD-L1 constructs.
  • the fucosylated construct is shown with gray squares connected by a dashed line, and the afucosylated construct is shown with black circles connected by a solid line.
  • a novel therapeutic disclosed herein has a biological activity greater than that of the known Fc-domain containing therapeutic, e.g., a known therapeutic antibody.
  • the presence of at least two Fc domains can enhance effector functions and to activate multiple effector functions, such as ADCC in combination with ADCP and/or CDC, thereby increasing the efficacy of the therapeutic molecules.
  • control of the number of Fc domains is critical.
  • the disclosure features a set of Fc engineering tools to control homodimerization and heterodimerization of the peptides encoding the Fc domain, to assemble molecules of discrete size from a limited number of polypeptide chains.
  • the engineering tools include structural features (for example, glycine linkers) that significantly improve manufacturing outcome.
  • the properties of these constructs allow for the efficient generation of substantially homogenous
  • Such homogeneity in a pharmaceutical composition is desirable in order to ensure the safety, efficacy, uniformity, and reliability of the pharmaceutical composition. Having a high degree of homogeneity in a pharmaceutical composition also minimizes potential aggregation or degradation of the pharmaceutical product caused by unwanted materials (e.g., degradation products, and/or aggregated products or multimers), as well as limiting off-target and adverse side effects caused by the unwanted materials.
  • unwanted materials e.g., degradation products, and/or aggregated products or multimers
  • Fc-antigen binding domain constructs in which Fc domains were connected in tandem, using one long peptide chain containing multiple Fc sequences separated by linkers, and multiple copies of a short chain containing a single Fc sequence (Fc-antigen binding domain constructs 1 -6; FIG. 1 -FIG. 6). Heterodimerizing mutations were introduced into each Fc sequence to ensure assembly into the desired tandem configuration with minimal formation of smaller or larger complexes. Any number of Fc domains can be connected in tandem in this fashion, allowing the creation of constructs with 2, 3, 4, 5, 6, 7, 8, 9, 10, or more Fc domains. For a peptide with N Fc domains, such constructs can be prepared with 1 to N+1 antigen binding domains, depending whether the antigen binding domains are introduced into the long peptide chain, the short peptide chain, or both, respectively.
  • Fc-antigen binding domain constructs 1 -6 Fc domains were connected with a single branch point between the Fc domains. These constructs include two copies of a long peptide chain containing multiple Fc sequences separated by linkers, in which the branching Fc sequence contains homodimerizing mutations and the non-branching Fc domains contain heterodimerizing mutations. Multiple copies of short chains including a single Fc sequence with mutations complementary to the heterodimerizing mutations in the long chains are used to complete the multimeric Fc scaffold. Heterodimerizing Fc domains can be linked to the C-terminal end (e.g., Fc-antigen binding domain constructs 7-12; FIG. 7-FIG.
  • Antigen binding domains may be introduced into the long peptide chains, resulting in two antigen binding domains per assembled protein molecule. Alternatively, antigen binding domains may be introduced into the short peptide chains, resulting in N-1 antigen binding domains per assembled protein molecule, where N is the number of Fc domains in the assembled protein molecule. If antigen binding domains are introduced into both the short and the long peptide chains, the resulting assembled protein molecule contains N+1 antigen binding domains.
  • Bispecific constructs may be generated from any of the above designs by using antigen binding domains in which two different antigen binding sequences are linked in tandem.
  • bispecific constructs may be generated from the above Fc scaffolds in which the long chain encodes for one antigen-binding domain, while the short chain encodes for a different antigen-binding domain.
  • the different antigen binding domains may use different light chains, or a common light chain, or may consist of scFv domains. Illustrative examples of this concept are Fc-antigen binding domain constructs 22-28 (FIG. 22-FIG. 28).
  • Bi-specific and tri-specific constructs may also be generated by the use of two different sets of heterodimerizing mutations (e.g., Fc-antigen binding domain constructs 29-42; FIG. 29-FIG. 42).
  • heterodimerizing sequences need to be designed in such a way that they disfavor association with the other heterodimerizing sequences.
  • Such designs can be accomplished using different electrostatic steering mutations between the two sets of heterodimerizing mutations as described herein.
  • orthogonal electrostatic steering mutations is E357K in the first knob Fc, K370D in first hole Fc, D399K in the second knob Fc, and K409D in the second hole Fc.
  • the Fc-antigen binding domain constructs disclosed in this disclosure unexpectedly feature stronger binding to multiple classes of Fey receptors and enhanced activity of multiple cytotoxicity pathways.
  • the Fc-antigen binding domain constructs of this disclosure can enhance binding to both FcyRIla and FcyRIIIa compared to their corresponding fucosylated and afucosylated parent monoclonal antibodies (see, Example 46).
  • the Fc-antigen binding domain constructs of this disclosure unexpectedly feature an ability to mediate the complement-dependent cytotoxicity (CDC) pathway and/or the antibody-dependent cellular phagocytosis (ADCP) pathway in addition to enhancing the ADCC pathway response (see, Example 47).
  • CDC complement-dependent cytotoxicity
  • ADCP antibody-dependent cellular phagocytosis
  • An Fc domain monomer includes at least a portion of a hinge domain, a CH2 antibody constant domain, and a CH3 antibody constant domain (e.g., a human lgG1 hinge, a CH2 antibody constant domain, and a CH3 antibody constant domain with optional amino acid substituions).
  • the Fc domain monomer can be of immunoglobulin antibody isotype IgG, IgE, IgM, IgA, or IgD.
  • the Fc domain monomer may also be of any immunoglobulin antibody isotype (e.g., IgG 1 , lgG2a, lgG2b, lgG3, or lgG4).
  • the Fc domain monomers may also be hybrids, e.g., with the hinge and CH2 from lgG1 and the CH3 from IgA, or with the hinge and CH2 from lgG1 but the CH3 from lgG3.
  • a dimer of Fc domain monomers is an Fc domain (further defined herein) that can bind to an Fc receptor, e.g., FcyRIIIa, which is a receptor located on the surface of leukocytes.
  • the CH3 antibody constant domain of an Fc domain monomer may contain amino acid substitutions at the interface of the CH3-CH3 antibody constant domains to promote their association with each other.
  • an Fc domain monomer includes an additional moiety, e.g., an albumin-binding peptide or a purification peptide, attached to the N- or C-terminus.
  • an Fc domain monomer does not contain any type of antibody variable region, e.g., VH, VL, a complementarity determining region (CDR), or a hypervariable region (HVR).
  • an Fc domain monomer in an Fc-antigen binding domain construct described herein may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of SEQ ID NO:42.
  • an Fc domain monomer in an Fc-antigen binding domain construct described herein may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of any one of SEQ ID NOs: 44, 46, 48, and 50-53.
  • an Fc domain monomer in the Fc-antigen binding domain construct may have a sequence that is at least 95% identical (at least 97%, 99%, or 99.5% identical) to the sequence of any one of SEQ ID NOs: 48, 52, and 53.
  • an Fc domain includes two Fc domain monomers that are dimerized by the interaction between the CH3 antibody constant domains.
  • An Fc domain forms the minimum structure that binds to an Fc receptor, e.g., Fc-gamma receptors (i.e., Fey receptors (FcyR)), Fc-alpha receptors (i.e., Fca receptors (FcaR)), Fc-epsilon receptors (i.e., Fes receptors (FcsR)), and/or the neonatal Fc receptor (FcRn).
  • Fc-gamma receptors i.e., Fey receptors (FcyR)
  • Fc-alpha receptors i.e., Fca receptors (FcaR)
  • Fc-epsilon receptors i.e., Fes receptors (FcsR)
  • FcRn neonatal Fc receptor
  • an Fc domain of the present disclosure binds to an Fey receptor (e.g., FcyRI (CD64), FcyRIla (CD32), FcyRIIb (CD32), FcyRIIIa (CD16a), FcyRIIIb (CD16b)), and/or FcyRIV and/or the neonatal Fc receptor (FcRn).
  • Fey receptor e.g., FcyRI (CD64), FcyRIla (CD32), FcyRIIb (CD32), FcyRIIIa (CD16a), FcyRIIIb (CD16b)
  • Antigen binding domains include one or more peptides or polypeptides that specifically bindi a target molecule.
  • Antigen binding domains may include the antigen binding domain of an antibody.
  • the antigen binding domain may be a fragment of an antibody or an antibody- construct, e.g., the minimal portion of the antibody that binds to the target antigen.
  • An antigen binding domain may also be a synthetically engineered peptide that binds a target specifically such as a fibronectin-based binding protein (e.g., a FN3 monobody).
  • a fragment antigen-binding (Fab) fragment is a region on an antibody that binds to a target antigen. It is composed of one constant and one variable domain of each of the heavy and the light chain.
  • a Fab fragment includes a VH, VL, CH1 and CL domains.
  • the variable domains VH and VL each contain a set of 3 complementarity-determining regions (CDRs) at the amino terminal end of the monomer.
  • the Fab fragment can be of immunoglobulin antibody isotype IgG, IgE, IgM, IgA, or IgD.
  • the Fab fragment monomer may also be of any combination of any combination of the monomer.
  • immunoglobulin antibody isotype e.g., lgG1 , lgG2a, lgG2b, lgG3, or lgG4.
  • a Fab fragment may be covalently attached to a second identical Fab fragment following protease treatment (e.g., pepsin) of an immunoglobulin, forming an F(ab’)2 fragment.
  • the Fab may be expressed as a single polypeptide, which includes both the variable and constant domains fused, e.g. with a linker between the domains.
  • a portion of a Fab fragment may be used as an antigen binding domain.
  • only the light chain component (VL + CL) of a Fab may be used, or only the heavy chain component (VH + CH) of a Fab may be used.
  • a single-chain variable fragment (scFv) which is a fusion protein of the the VH and VL chains of the Fab variable region, may be used.
  • a linear antibody which includes a pair of tandem Fd segments (VH-CH1 -VH-CH1 ), which, together with complementary light chain polypeptides form a pair of antigen binding regions, may be used.
  • an antigen binding domain of the present disclosure includes for a target or antigen listed in Table 1 , one, two, three, four, five, or all six of the CDR sequences listed in Table 1 for the listed target or antigen, as provided in further detail below Table 1 .
  • the antigen binding domain of Fc-antigen binding domain construct 1 (1 10/104 in FIG. 1) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domain of Fc-antigen binding domain construct 2 (212/204 in FIG. 2) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 3 (308/316 and 312/318 in FIG. 3) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 4 (410/412, 416/418 and 422/424 in FIG. 4) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 5 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 6 (612/604, 614/616, 620/622, and 626/628 in FIG. 6) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 7 (712/714 and 714/716 in FIG. 7) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 8 (812/806 and 818/822 in FIG. 8) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 9 (908/906, 920/922, 912/914, and 926/930 in FIG. 9) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 10 (1006/1004 and 1018/1020 in FIG. 10) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 1 1 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 12 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 13 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 14 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 15 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 16 (1616/1604 and 1618/1630 in FIG. 16) each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 17 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 18 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 19 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 20 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domains of Fc-antigen binding domain construct 21 each can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 22 (2204/2222 in FIG. 22) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 22 (each of 2218/2220 and 2212/2214 in FIG. 22) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 23 (2330/2304 in FIG. 23) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 23 (each of 2328/2326, 2322/2320, and 2316/2314 in FIG. 23) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2430/2428 and 2420/2422 in FIG. 24) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2432/2406 and 2418/2416 in FIG. 24) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2532/2506 and 2530/2528 in FIG. 25) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2510/2512 and 2524/2522 in FIG. 25) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2648/2646 and 2634/2636 in FIG. 26) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2612/2614, 2650/2608, 2632/2630, and 2626/2624 in FIG. 26) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2748/2746 and 2738/2740 in FIG. 27) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2714/2716, 2750/2708, 2736/2734, and 2728/2726 in FIG. 27) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2850/2808 and 2848/2846 in FIG. 27) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2818/2820, 2812/2814, 2842/2840, and 2836/2834 in FIG. 28) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2918/2904 in FIG. 29) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2914/2912 in FIG. 29) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 30 (each of 3022/3004 and 3020/3018 in FIG. 30) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 30 (3014/3012 in FIG. 30) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 31 (3122/3104 in FIG. 31) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 31 (3120/31 18 in FIG. 31) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 31 (31 14/31 12 in FIG. 31) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 32 (3226/3204 in FIG. 32) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 32 (each of 3222/3220 and 3216/3214 in FIG. 32) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3330/3304 and 3328/3326 in FIG. 33) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3322/3320 and 3316/3314 in FIG. 33) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3430/3404 in FIG. 34) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3428/3426 in FIG. 34) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 34 (each of 3422/3420 and 3416/3414 in FIG. 34) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 35 (each of 3530/3528 and 3520/3522 in FIG. 35) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3532/3506 in FIG. 35) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3518/3516 in FIG. 35) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3638/3636 and 3628/3620 in FIG. 36) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3640/3606 and 3626/3624 in FIG. 36) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3748/3746 and 3738/3740 in FIG. 37) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3750/3708 and 3736/3734in FIG. 37) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3714/3716 and 3728/3726 in FIG. 37) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 38 (each of 3832/3806 and 3830/3822 in FIG. 38) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3810/3812 in FIG. 38) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3824/3822 in FIG. 38) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3938/3936 and 3924/3926 in FIG. 39) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3940/3906 and 3922/3920 in FIG. 39) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4048/4046 and 4034/4036 in FIG. 40) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4050/4008 and 4032/4030 in FIG. 40) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4012/4014 and 4026/4024 in FIG. 40) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 4140/4106 and 4138/4136 in FIG. 41) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 41 12/41 14 and 4130/4128 in FIG. 41) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4250/4208 and 4248/4246 in FIG. 42) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4218/4220 and 4236/4234 in FIG. 42) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4212/4214 and 4242/4240 in FIG. 42) can include the three heavy chain and the three light chain CDR sequences of any one of the antibodies listed in Table 1 .
  • the antigen binding domain (e.g., a Fab or a scFv) includes the VH and VL chains of an antibody listed in Table 2.
  • the Fab includes the CDRs contained in the VH and VL chains of an antibody listed in Table 2.
  • the Fab includes the CDRs contained in the VH and VL chains of an antibody listed in Table 2 and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of an antibody in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 1 (110/104 in FIG. 1) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 2 (212/204 in FIG. 2) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 3 (308/316 and 312/318 in
  • FIG. 3 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 4 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 5 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 6 (612/604, 614/616, 620/622, and 626/628 in FIG. 6) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 7 (712/714 and 714/716 in FIG. 7) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 8 (812/806 and 818/822 in FIG. 8) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 9 (908/906, 920/922, 912/914, and 926/930 in FIG. 9) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 10 (1006/1004 and 1018/1020 in FIG. 10) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 1 1 (1 1 12/1 1 14, 1 122/1 108, 1 128/1 142, and 1 138/1 136 in FIG. 1 1) each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 12 each can include the VH and V L sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 13 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 14 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 15 (1508/1506, 1514/1516,
  • the antigen binding domains of Fc-antigen binding domain construct 16 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 17 (1712/1714, 1724/1708,
  • the antigen binding domains of Fc-antigen binding domain construct 18 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 20 each can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 21 each can include the VH and V L sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (2204/2222 in FIG. 22) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (each of 2218/2220 and 2212/2214 in FIG. 22) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (2330/2304 in FIG. 23) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (each of 2328/2326, 2322/2320, and 2316/2314 in FIG. 23) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2430/2428 and 2420/2422 in FIG. 24) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2432/2406 and 2418/2416 in FIG. 24) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2532/2506 and 2530/2528 in FIG. 25) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2510/2512 and 2524/2522 in FIG. 25) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2648/2646 and 2634/2636 in FIG. 26) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2612/2614, 2650/2608, 2632/2630, and 2626/2624 in FIG. 26) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2748/2746 and 2738/2740 in FIG. 27) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2714/2716, 2750/2708, 2736/2734, and 2728/2726 in FIG. 27) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2850/2808 and 2848/2846 in FIG. 27) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2818/2820, 2812/2814, 2842/2840, and 2836/2834 in FIG. 28) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2918/2904 in FIG. 29) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2914/2912 in FIG. 29) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (each of 3022/3004 and 3020/3018 in FIG. 30) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (3014/3012 in FIG. 30) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (122/3104 in FIG. 31) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (120/31 18 in FIG. 31) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (31 14/31 12 in FIG. 31) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (3226/3204 in FIG. 32) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (each of 3222/3220 and 3216/3214 in FIG. 32) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3330/3304 and 3328/3326 in FIG. 33) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3322/3320 and 3316/3314 in FIG. 33) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3430/3404 in FIG. 34) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3428/3426 in FIG. 34) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (each of 3422/3420 and 3416/3414 in FIG. 34) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (each of 3530/3528 and 3520/3522 in FIG. 35) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3532/3506 in FIG. 35) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3518/3516 in FIG. 35) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3638/3636 and 3628/3620 in FIG. 36) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3640/3606 and 3626/3624 in FIG. 36) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3748/3746 and 3738/3740 in FIG. 37) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3750/3708 and 3736/3734in FIG. 37) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3714/3716 and 3728/3726 in FIG. 37) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (each of 3832/3806 and 3830/3822 in FIG. 38) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3810/3812 in FIG. 38) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3824/3822 in FIG. 38) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3938/3936 and 3924/3926 in FIG. 39) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3940/3906 and 3922/3920 in FIG. 39) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4048/4046 and 4034/4036 in FIG. 40) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4050/4008 and 4032/4030 in FIG. 40) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4012/4014 and 4026/4024 in FIG. 40) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 4140/4106 and 4138/4136 in FIG. 41) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 41 12/41 14 and 4130/4128 in FIG. 41) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4250/4208 and 4248/4246 in FIG. 42) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4218/4220 and 4236/4234 in FIG. 42) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4212/4214 and 4242/4240 in FIG. 42) can include the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 1 (1 10/104 in FIG. 1) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 2 (212/204 in FIG. 2) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 3 (308/316 and 312/318 in FIG. 3) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 4 (410/412, 416/418 and 422/424 in FIG. 4) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 5 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 6 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 7 (712/714 and 714/716 in FIG. 7) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 8 (812/806 and 818/822 in FIG. 8) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 9 (908/906, 920/922, 912/914, and 926/930 in FIG. 9) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 10 (1006/1004 and
  • each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 1 1 (1 1 12/1 1 14, 1 122/1 108, 1 128/1 142, and 1 138/1 136 in FIG. 1 1) each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 12 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 13 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 14 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 15 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 16 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 17 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 18 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 19 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 20 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 21 each can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (2204/2222 in FIG. 22) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (each of 2218/2220 and 2212/2214 in FIG. 22) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (2330/2304 in FIG. 23) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (each of 2328/2326, 2322/2320, and 2316/2314 in FIG. 23) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2430/2428 and 2420/2422 in FIG. 24) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2432/2406 and 2418/2416 in FIG. 24) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2532/2506 and 2530/2528 in FIG. 25) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2510/2512 and 2524/2522 in FIG. 25) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2648/2646 and 2634/2636 in FIG. 26) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2612/2614, 2650/2608, 2632/2630, and 2626/2624 in FIG. 26) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2748/2746 and 2738/2740 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2714/2716, 2750/2708, 2736/2734, and 2728/2726 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2850/2808 and 2848/2846 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2818/2820, 2812/2814, 2842/2840, and 2836/2834 in FIG. 28) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2918/2904 in FIG. 29) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2914/2912 in FIG. 29) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (each of 3022/3004 and 3020/3018 in FIG. 30) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (3014/3012 in FIG. 30) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (3122/3104 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (120/31 18 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (31 14/31 12 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (3226/3204 in FIG. 32) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (each of 3222/3220 and 3216/3214 in FIG. 32) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3330/3304 and 3328/3326 in FIG. 33) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3322/3320 and 3316/3314 in FIG. 33) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3430/3404 in FIG. 34) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3428/3426 in FIG. 34) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (each of 3422/3420 and 3416/3414 in FIG. 34) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (each of 3530/3528 and 3520/3522 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3532/3506 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3518/3516 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3638/3636 and 3628/3620 in FIG. 36) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3640/3606 and 3626/3624 in FIG. 36) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3748/3746 and 3738/3740 in FIG. 37) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3750/3708 and 3736/3734in FIG. 37) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3714/3716 and 3728/3726 in FIG. 37) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (each of 3832/3806 and 3830/3822 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3810/3812 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3824/3822 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3938/3936 and 3924/3926 in FIG. 39) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 (each of 3940/3906 and 3922/3920 in FIG. 39) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4048/4046 and 4034/4036 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4050/4008 and 4032/4030 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4012/4014 and 4026/4024 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 4140/4106 and 4138/4136 in FIG. 41) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 41 12/41 14 and 4130/4128 in FIG. 41) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4250/4208 and 4248/4246 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4218/4220 and 4236/4234 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4212/4214 and 4242/4240 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 1 (1 10/104 in FIG. 1) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domain of Fc-antigen binding domain construct 2 (212/204 in FIG. 2) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 3 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 4 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 5 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 6 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 7 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 8 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 9 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 10 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 1 1 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 12 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 13 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 14 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 15 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 16 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 17 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 18 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 19 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 20 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • the antigen binding domains of Fc-antigen binding domain construct 21 each can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (2204/2222 in FIG. 22) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 22 (each of 2218/2220 and 2212/2214 in FIG. 22) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (2330/2304 in FIG.
  • VH and VL sequences 23 can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 23 (each of 2328/2326, 2322/2320, and 2316/2314 in FIG. 23) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2430/2428 and 2420/2422 in FIG. 24) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 24 (each of 2432/2406 and 2418/2416 in FIG. 24) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2532/2506 and 2530/2528 in FIG. 25) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 25 (each of 2510/2512 and 2524/2522 in FIG. 25) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2648/2646 and 2634/2636 in FIG. 26) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 26 (each of 2612/2614, 2650/2608, 2632/2630, and 2626/2624 in FIG. 26) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2748/2746 and 2738/2740 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 27 (each of 2714/2716, 2750/2708, 2736/2734, and 2728/2726 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2850/2808 and 2848/2846 in FIG. 27) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 28 (each of 2818/2820, 2812/2814, 2842/2840, and 2836/2834 in FIG. 28) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2918/2904 in FIG. 29) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 29 (2914/2912 in FIG. 29) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (each of 3022/3004 and 3020/3018 in FIG. 30) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 30 (3014/3012 in FIG. 30) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (3122/3104 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (120/31 18 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 31 (31 14/31 12 in FIG. 31) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (3226/3204 in FIG. 32) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 32 (each of 3222/3220 and 3216/3214 in FIG. 32) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3330/3304 and 3328/3326 in FIG. 33) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 33 (each of 3322/3320 and 3316/3314 in FIG. 33) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3430/3404 in FIG. 34) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (3428/3426 in FIG.
  • VH and VL sequences 34 can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 34 (each of 3422/3420 and 3416/3414 in FIG. 34) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (each of 3530/3528 and 3520/3522 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3532/3506 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 35 (3518/3516 in FIG. 35) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3638/3636 and 3628/3620 in FIG. 36) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 36 (each of 3640/3606 and 3626/3624 in FIG. 36) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3748/3746 and 3738/3740 in FIG. 37) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3750/3708 and 3736/3734in FIG.
  • VH and VL sequences can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 37 (each of 3714/3716 and 3728/3726 in FIG. 37) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (each of 3832/3806 and 3830/3822 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3810/3812 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 38 (3824/3822 in FIG. 38) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 39 can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4048/4046 and 4034/4036 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4050/4008 and 4032/4030 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 40 (each of 4012/4014 and 4026/4024 in FIG. 40) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 4140/4106 and 4138/4136 in FIG. 41) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 41 (each of 41 12/41 14 and 4130/4128 in FIG. 41 ) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4250/4208 and 4248/4246 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4218/4220 and 4236/4234 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • An antigen binding domain of Fc-antigen binding domain construct 42 (each of 4212/4214 and 4242/4240 in FIG. 42) can include the CDR sequences contained in the VH and VL sequences, and the remainder of the VH and VL sequences are at least 95% identical, at least 97% identical, at least 99% identical, or at least 99.5% identical to the VH and VL sequences of any one of the antibodies listed in Table 2.
  • a dimerization selectivity module includes components or select amino acids within the Fc domain monomer that facilitate the preferred pairing of two Fc domain monomers to form an Fc domain.
  • a dimerization selectivity module is that part of the CH3 antibody constant domain of an Fc domain monomer which includes amino acid substitutions positioned at the interface between interacting CH3 antibody constant domains of two Fc domain monomers.
  • the amino acid substitutions make favorable the dimerization of the two CH3 antibody constant domains as a result of the compatibility of amino acids chosen for those substitutions.
  • the ultimate formation of the favored Fc domain is selective over other Fc domains which form from Fc domain monomers lacking dimerization selectivity modules or with incompatible amino acid substitutions in the dimerization selectivity modules.
  • This type of amino acid substitution can be made using conventional molecular cloning techniques well-known in the art, such as QuikChange ® mutagenesis.
  • a dimerization selectivity module includes an engineered cavity (of“hole” described further herein) in the CH3 antibody constant domain.
  • a dimerization selectivity module includes an engineered protuberance (or“knob” described further herein) in the CH3 antibody constant domain.
  • two Fc domain monomers with compatible dimerization selectivity modules e.g., one CH3 antibody constant domain containing an engineered cavity and the other CH3 antibody constant domain containing an engineered protuberance, combine to form a protuberance-into-cavity (or“knob and hole”) pair of Fc domain monomers.
  • Engineered protuberances and engineered cavities are examples of heterodimerizing selectivity modules, which can be made in the CH3 antibody constant domains of Fc domain monomers in order to promote favorable heterodimerization of two Fc domain monomers that have compatible heterodimerizing selectivity modules.
  • Table 3 lists suitable mutation.
  • heterodimerization is achieved by use of an Fc domain monomer with a dimerization selectivity module containing positively-charged amino acid substitutions and an Fc domain monomer with a dimerization selectivity module containing negatively-charged amino acid substitutions may selectively combine to form an Fc domain through the favorable electrostatic steering (described further herein) of the charged amino acids.
  • an Fc domain monomer may include one of the following positively-charged and negatively-charged amino acid substitutions: K392D, K392E, D399K, K409D, K409E, K439D, and K439E.
  • an Fc domain monomer containing a positively-charged amino acid substitution e.g., D356K or E357K
  • an Fc domain monomer containing a negatively-charged amino acid substitution e.g., K370D or K370E
  • an Fc domain monomer containing E357K and an Fc domain monomer containing K370D may selectively combine to form an Fc domain through favorable electrostatic steering of the charged amino acids.
  • reverse charge amino acid substitutions may be used as heterodimerizing selectivity modules, wherein two Fc domain monomers containing different, but compatible, reverse charge amino acid substitutions combine to form a heterodimeric Fc domain.
  • Table 3 lists various reverse charged dimerization selectivity modules for promoting heterodimerization.
  • two Fc domain monomers include homodimerizing selectivity modules containing identical reverse charge mutations in at least two positions within the ring of charged residues at the interface between CH3 domains.
  • Homodimerizing selectivity modules are reverse charge amino acid substitutions that promote the homodimerization of Fc domain monomers to form a homodimeric Fc domain.
  • mutated Fc domain monomers remain complementary to Fc domain monomers of the same mutated sequence, but have a lower complementarity to Fc domain monomers without those mutations.
  • an Fc domain includes Fc domain monomers including the double mutants K409D/D399K, K392D/D399K, E357K/K370E, D356K/K439D, K409E/D399K,
  • an Fc domain includes Fc domain monomers including quadruple mutants combining any pair of the double mutants, e.g.,
  • an Fc domain monomer containing (i) at least one reverse charge mutation and (ii) at least one engineered cavity or at least one engineered protuberance may selectively combine with another Fc domain monomer containing (i) at least one reverse charge mutation and (ii) at least one engineered protuberance or at least one engineered cavity to form an Fc domain.
  • an Fc domain monomer containing reversed charge mutation K370D and engineered cavities Y349C, T366S, L368A, and Y407V and another Fc domain monomer containing reversed charge mutation E357K and engineered protuberances S354C and T366W may selectively combine to form an Fc domain.
  • Fc domains are promoted by the compatible amino acid substitutions in the CH3 antibody constant domains.
  • Two dimerization selectivity modules containing incompatible amino acid substitutions e.g., both containing engineered cavities, both containing engineered protuberances, or both containing the same charged amino acids at the CH3-CH3 interface, will not promote the formation of a heterodimeric Fc domain.
  • WO2011034605 which includes C-terminal fusion of a monomer a-helices of a leucine zipper to each of the Fc domain monomers to allow heterodimer formation, as well as strand-exchange engineered domain (SEED) body approach (Davis et al., Protein Eng Des Sel. 23:195-202, 2010) that generates Fc domain with heterodimeric Fc domain monomers each including alternating segments of IgA and IgG CH3 sequences.
  • SEED strand-exchange engineered domain
  • engineered cavities and engineered protuberances are used in the preparation of the Fc-antigen binding domain constructs described herein.
  • An engineered cavity is a void that is created when an original amino acid in a protein is replaced with a different amino acid having a smaller side-chain volume.
  • An engineered protuberance is a bump that is created when an original amino acid in a protein is replaced with a different amino acid having a larger side-chain volume.
  • the amino acid being replaced is in the CH3 antibody constant domain of an Fc domain monomer and is involved in the dimerization of two Fc domain monomers.
  • an engineered cavity in one CH3 antibody constant domain is created to accommodate an engineered protuberance in another CH3 antibody constant domain, such that both CH3 antibody constant domains act as dimerization selectivity modules (e.g., heterodimerizing selectivity modules) (described above) that promote or favor the dimerization of the two Fc domain monomers.
  • dimerization selectivity modules e.g., heterodimerizing selectivity modules
  • an engineered cavity in one CH3 antibody constant domain is created to better accommodate an original amino acid in another CH3 antibody constant domain.
  • an engineered protuberance in one CH3 antibody constant domain is created to form additional interactions with original amino acids in another CH3 antibody constant domain.
  • An engineered cavity can be constructed by replacing amino acids containing larger side chains such as tyrosine or tryptophan with amino acids containing smaller side chains such as alanine, valine, or threonine.
  • some dimerization selectivity modules e.g., heterodimerizing selectivity modules
  • engineered cavities such as Y407V mutation in the CH3 antibody constant domain.
  • an engineered protuberance can be constructed by replacing amino acids containing smaller side chains with amino acids containing larger side chains.
  • some dimerization selectivity modules e.g., heterodimerizing selectivity modules
  • contain engineered protuberances such as T366W mutation in the CH3 antibody constant domain.
  • engineered cavities and engineered protuberances are also combined with inter-C H 3 domain disulfide bond engineering to enhance heterodimer formation.
  • an Fc domain monomer containing engineered cavities Y349C, T366S, L368A, and Y407V may selectively combine with another Fc domain monomer containing engineered protuberances S354C and T366W to form an Fc domain.
  • an Fc domain monomer containing an engineered cavity with the addition of Y349C and an Fc domain monomer containing an engineered protuberance with the addition of S354C may selectively combine to form an Fc domain.
  • protuberances in combination with either disulfide bond engineering or structural calculations (mixed HA- TF) are included, without limitation, in Table 3.
  • Replacing an original amino acid residue in the CH3 antibody constant domain with a different amino acid residue can be achieved by altering the nucleic acid encoding the original amino acid residue.
  • the upper limit for the number of original amino acid residues that can be replaced is the total number of residues in the interface of the CH3 antibody constant domains, given that sufficient interaction at the interface is still maintained.
  • Electrostatic steering can be combined with knob-in-hole technology to favor heterominerization, for example, between Fc domain monomers in two different polypeptides.
  • Electrostatic steering described in greater detail below, is the utilization of favorable electrostatic interactions between oppositely charged amino acids in peptides, protein domains, and proteins to control the formation of higher ordered protein molecules. Electrostatic steering can be used to promote either homodimerization or heterodimerization, the latter of which can be usefully combined with knob-in-hole technology.
  • heterodimerization different, but compatible, mutations are introduced in each of the Fc domain monomers which are to heterodimerize.
  • an Fc domain monomer can be modified to include one of the following positively-charged and negatively-charged amino acid substitutions: D356K, D356R, E357K, E357R, K370D, K370E, K392D, K392E, D399K, K409D, K409E, K439D, and K439E.
  • one Fc domain monomer for example, an Fc domain monomer having a cavity (Y349C, T366S, L368A and Y407V), can also include K370D mutation and the other Fc domain monomer, for example, an Fc domain monomer having a protuberance (S354C and T366W) can include E357K.
  • any of the cavity mutations can be combined with an electrostatic steering mutation in Table 3 and any of the protuberance mutations (or mutation combinations): T366Y, T366W, T394W, F405W, T366Y:F405A, T366W:Y407A, T366W:S354C, and Y349T:T394F can be combined with an electrostatic steering mutation in Table that is paired with the Table 3 electrostatic steering mutation used in combination with the cavity mutation (or mutation combination).
  • any of the cavity mutations can be combined with an electrostatic steering mutation in Table 3 and any of the protuberance mutations (or mutation combinations): T366Y, T366W, T394W, F405W, T366Y:F405A, T366W:Y407A, T366W:S354C, and Y349T:T394F can be combined with an electrostatic steering mutation in Table 3.
  • Electrostatic steering is the utilization of favorable electrostatic interactions between oppositely charged amino acids in peptides, protein domains, and proteins to control the formation of higher ordered protein molecules.
  • a method of using electrostatic steering effects to alter the interaction of antibody domains to reduce for formation of homodimer in favor of heterodimer formation in the generation of bi-specific antibodies is disclosed in U.S. Patent Application Publication No. 2014-0024111.
  • electrostatic steering is used to control the dimerization of Fc domain monomers and the formation of Fc-antigen binding domain constructs.
  • one or more amino acid residues that make up the CH3-CH3 interface are replaced with positively- or negatively-charged amino acid residues such that the interaction becomes electrostatically favorable or unfavorable depending on the specific charged amino acids introduced.
  • a positively-charged amino acid in the interface such as lysine, arginine, or histidine, is replaced with a negatively-charged amino acid such as aspartic acid or glutamic acid.
  • a negatively-charged amino acid in the interface is replaced with a positively-charged amino acid.
  • the charged amino acids may be introduced to one of the interacting CH3 antibody constant domains, or both.
  • dimerization selectivity modules (described further above) are created that can selectively form dimers of Fc domain monomers as controlled by the electrostatic steering effects resulting from the interaction between charged amino acids.
  • the two Fc domain monomers may be selectively formed through heterodimerization or homodimerization.
  • an Fc domain monomer may include one of the following positively-charged and negatively-charged amino acid substitutions: D356K, D356R, E357K, E357R, K370D, K370E, K392D, K392E, D399K, K409D, K409E, K439D, and K439E.
  • an Fc domain monomer containing a positively-charged amino acid substitution e.g., D356K or E357K
  • an Fc domain monomer containing a negatively-charged amino acid substitution e.g., K370D or K370E
  • an Fc domain monomer containing E357K and an Fc domain monomer containing K370D may selectively combine to form an Fc domain through favorable electrostatic steering of the charged amino acids.
  • heterodimeric Fc domain refers to an Fc domain that is formed by the heterodimerization of two Fc domain monomers, wherein the two Fc domain monomers contain different reverse charge mutations (heterodimerizing selectivity modules) (see, e.g., mutations in Tables 4A and 4B) that promote the favorable formation of these two Fc domain monomers.
  • each of the amino terminal“branch” Fc domains may be a heterodimeric Fc domain (also called a“branch heterodimeric Fc domain”) (e.g., a heterodimeric Fc domain formed by Fc domain monomers 106 and 114 or Fc domain monomers 112 and 116 in FIG. 1 ; a heterodimeric Fc domain formed by Fc domain monomers 206 and 214 or Fc domain monomers 212 and 216 in FIG. 2).
  • a branch heterodimeric Fc domain may be formed by an Fc domain monomer containing E357K and another Fc domain monomer containing K370D.
  • Fc domain monomers Homodimerization of Fc domain monomers can be promoted by introducing the same electrostatic steering mutations (homodimerizing selectivity modules) in both Fc domain monomers in a symmetric fashion.
  • two Fc domain monomers include homodimerizing selectivity modules containing identical reverse charge mutations in at least two positions within the ring of charged residues at the interface between CH3 domains. By reversing the charge of both members of two or more complementary pairs of residues in the two Fc domain monomers, mutated Fc domain monomers remain complementary to Fc domain monomers of the same mutated sequence, but have a lower
  • an Fc domain includes two Fc domain monomers each including the double reverse charge mutants (Tables 4A and 4B), e.g., K409D/D399K.
  • an Fc domain includes two Fc domain monomers each including quadruple reverse mutants (Tables 4A and 4B), e.g., K409D/D399K/K370D/E357K.
  • one of the three Fc domains may be formed by the homodimerization of two Fc domain monomers, as promoted by the electrostatic steering effects.
  • A“homodimeric Fc domain” refers to an Fc domain that is formed by the homodimerization of two Fc domain monomers, wherein the two Fc domain monomers contain the same reverse charge mutations (see, e.g., mutations in Tables 5 and 6).

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
PCT/US2019/041438 2018-07-11 2019-07-11 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS Ceased WO2020014505A2 (en)

Priority Applications (10)

Application Number Priority Date Filing Date Title
CN201980059592.5A CN113382749A (zh) 2018-07-11 2019-07-11 与工程化Fc-抗原结合结构域构建体有关的组合物和方法
KR1020217004250A KR20210043582A (ko) 2018-07-11 2019-07-11 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법
BR112021000415-7A BR112021000415A2 (pt) 2018-07-11 2019-07-11 Composições e métodos relacionados a construtos do domínio de ligação fc-antígeno manipulados
AU2019301684A AU2019301684A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered Fc-antigen binding domain constructs
US17/259,443 US20210317227A1 (en) 2018-07-11 2019-07-11 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS
CA3106242A CA3106242A1 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs
MX2021000280A MX2021000280A (es) 2018-07-11 2019-07-11 Composiciones y métodos relacionados con constructos de dominio de unión a antígeno-fc modificados genéticamente.
JP2021500881A JP2021530992A (ja) 2018-07-11 2019-07-11 改変されたＦｃ抗原結合ドメイン構築体に関する組成物および方法
EP19833960.8A EP3820518A4 (en) 2018-07-11 2019-07-11 Compositions and methods related to engineered fc-antigen binding domain constructs
IL280044A IL280044A (en) 2018-07-11 2021-01-10 Compositions and methods relating to engineered constructs with an antigen-binding site-FC

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862696673P 2018-07-11 2018-07-11
US62/696,673 2018-07-11

Publications (2)

Publication Number Publication Date
WO2020014505A2 true WO2020014505A2 (en) 2020-01-16
WO2020014505A3 WO2020014505A3 (en) 2020-02-20

Family

ID=69141701

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2019/041438 Ceased WO2020014505A2 (en) 2018-07-11 2019-07-11 COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS

Country Status (11)

Country Link
US (1) US20210317227A1 (https=)
EP (1) EP3820518A4 (https=)
JP (1) JP2021530992A (https=)
KR (1) KR20210043582A (https=)
CN (1) CN113382749A (https=)
AU (1) AU2019301684A1 (https=)
BR (1) BR112021000415A2 (https=)
CA (1) CA3106242A1 (https=)
IL (1) IL280044A (https=)
MX (1) MX2021000280A (https=)
WO (1) WO2020014505A2 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021234655A3 (en) * 2020-05-21 2022-01-06 Cadila Healthcare Limited Fc variant and preparation thereof
WO2022143912A1 (zh) * 2020-12-31 2022-07-07 信达生物制药(苏州)有限公司 含异二聚体抗体Fc的蛋白以及其制备方法
JP2023535677A (ja) * 2020-07-10 2023-08-21 バイオモレキュラー・ホールディングス・エルエルシー 四面体抗体

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101835802B (zh) * 2007-06-01 2014-04-09 马里兰大学巴尔的摩分校 免疫球蛋白恒定区Fc受体结合剂
EP2409989A1 (en) * 2010-07-19 2012-01-25 International-Drug-Development-Biotech Method to improve glycosylation profile for antibody
EP2748197A2 (en) * 2011-08-26 2014-07-02 Merrimack Pharmaceuticals, Inc. Tandem fc bispecific antibodies
JP2015527366A (ja) * 2012-08-20 2015-09-17 グリックニック インコーポレイテッド 抗原結合および多価ｆｃガンマ受容体結合活性を有する分子
KR20200024345A (ko) * 2013-01-10 2020-03-06 젠맵 비. 브이 인간 IgG1 Fc 영역 변이체 및 그의 용도
UA117289C2 (uk) * 2014-04-02 2018-07-10 Ф. Хоффманн-Ля Рош Аг Мультиспецифічне антитіло
JP2017518965A (ja) * 2014-05-02 2017-07-13 モメンタ ファーマシューティカルズ インコーポレイテッ エンジニアリングされたＦｃ構築物に関連する組成物および方法
WO2017044699A1 (en) * 2015-09-10 2017-03-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-cd276 chimeric antigen receptors
WO2017151971A2 (en) * 2016-03-02 2017-09-08 Momenta Pharmaceuticals, Inc. METHODS RELATED TO ENGINEERED Fc CONSTRUCTS
BR112018074056A2 (pt) * 2016-05-23 2019-03-06 Momenta Pharmaceuticals, Inc. composições e métodos relacionados a construtos de fc manipulados
CA3043251A1 (en) * 2016-12-09 2018-06-14 Gliknik Inc. Methods of treating inflammatory disorders with multivalent fc compounds
RU2019124709A (ru) * 2017-01-06 2021-02-08 Момента Фармасьютикалз, Инк. КОМПОЗИЦИИ И СПОСОБЫ, СВЯЗАННЫЕ СО СКОНСТРУИРОВАННЫМИ КОНСТРУКЦИЯМИ НА ОСНОВЕ Fc-АНТИГЕНСВЯЗЫВАЮЩЕГО ДОМЕНА

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021234655A3 (en) * 2020-05-21 2022-01-06 Cadila Healthcare Limited Fc variant and preparation thereof
JP2023535677A (ja) * 2020-07-10 2023-08-21 バイオモレキュラー・ホールディングス・エルエルシー 四面体抗体
EP4178615A4 (en) * 2020-07-10 2024-07-24 Biomolecular Holdings LLC TETRAHEDRAL ANTIBODIES
WO2022143912A1 (zh) * 2020-12-31 2022-07-07 信达生物制药(苏州)有限公司 含异二聚体抗体Fc的蛋白以及其制备方法

Also Published As

Publication number Publication date
CN113382749A (zh) 2021-09-10
MX2021000280A (es) 2021-11-12
WO2020014505A3 (en) 2020-02-20
US20210317227A1 (en) 2021-10-14
BR112021000415A2 (pt) 2021-04-06
IL280044A (en) 2021-03-01
EP3820518A4 (en) 2022-06-29
EP3820518A2 (en) 2021-05-19
CA3106242A1 (en) 2020-01-16
JP2021530992A (ja) 2021-11-18
AU2019301684A1 (en) 2021-02-18
KR20210043582A (ko) 2021-04-21

Similar Documents

Publication Publication Date Title
US20200040084A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
EP3820521A2 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ctla-4
US20210269546A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38
WO2020014486A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
EP3820518A2 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
US20210147549A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO PD-L1
WO2020014429A2 (en) Compositions and methods related to engineered fc-antigen binding domain constructs targeted to ccr4
WO2020014545A1 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
EP3820910A2 (en) Compositions and methods related to engineered fc-antigen binding domain constructs
WO2021055876A1 (en) COMPOSITIONS AND METHODS RELATED TO ENGINEERED Fc-ANTIGEN BINDING DOMAIN CONSTRUCTS TARGETED TO CD38

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19833960

Country of ref document: EP

Kind code of ref document: A2

ENP Entry into the national phase

Ref document number: 3106242

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2021500881

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE

REG Reference to national code

Ref country code: BR

Ref legal event code: B01A

Ref document number: 112021000415

Country of ref document: BR

ENP Entry into the national phase

Ref document number: 20217004250

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019301684

Country of ref document: AU

Date of ref document: 20190711

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2019833960

Country of ref document: EP

Effective date: 20210211

ENP Entry into the national phase

Ref document number: 112021000415

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20210111

WWW Wipo information: withdrawn in national office

Ref document number: 2021103197

Country of ref document: RU

WWW Wipo information: withdrawn in national office

Ref document number: 280044

Country of ref document: IL